Benzopyran derivatives

ABSTRACT

Benzopyran derivatives of the formula: ##STR1## and the pharmaceutically acceptable acid addition salts thereof possess the inhibitory activity on Maillard reaction and an antioxidizing effect, and therefore, are useful for the prevention and treatment of several diabetic complications, diseases induced by aging and several diseases caused by formation of peroxidized fat.

This is a divisional of application Ser. No. 07/736,321 filed Jul. 26,1991, now U.S. Pat. No. 5,169,457, which is a divisional of applicationSer. No. 07/491,876, filed Mar. 12, 1990, now U.S. Pat. No. 5,055,598.

SUMMARY

This invention is related to benzopyran derivatives which are useful formedicines.

More particularly, this invention is related to

1) benzopyran derivatives of the formula: ##STR2## (wherein all of thesymbols are the same meanings as hereinafter defined) andpharmaceutically acceptable acid addition salts thereof,

2) processes for the preparation of them, and

3) inhibitory agents on Maillard reaction and antioxidants containingthe compound of the formula: ##STR3## (wherein all of the symbols arethe same meaning as hereinafter defined), which includes the compoundsof the formula (IA), as active ingredient.

BACKGROUND

In 1912, Maillard reported that, when a mixture of amino acid andreducing sugar is heated, it shows brown color (called browningphenomenon). (Maillard, L. C., Compt. Rend. Soc. Biol., 72, 599 (1912)),and suggested that this reaction might occur in a body. In 1968, Rahbarreported that HbAlc, the glycosylated part of haemoglobin (Hg), wasincreased in diabetics (Rahbar, S., Clin. Chim. Acta., 22, 296 (1968)).Afterwards, it became clean that HbAlc had the chemical structure inwhich glucose binds to valine in N-terminal side of β-chain in the formof Amadori rearrangement (Koeing, R. J., Blobstein, S. H., & Cerami, A.,J. Biol. Chem., 252, 2992 (1977)), and that Maillard reaction proceedsnonenzymatically (Stevens, V. J., Vlassara, H., Abati, A., & Cerami, A.,J. Biol. Chem., 252, 2998 (1977)). These results showed that Maillardreaction occurs in a body.

As an initial step, Maillard reaction consists of forming the Amadorirearrangement products by glycosylation of reducing sugar withamino-group of protein. In the advanced stage of this reaction

(1) cross-linked compounds (called advanced glycosylation and products(abbreviated as "AGE")) are produced,

(2) solubility of them becomes low,

(3) the products can not be easily degraded by the action of proteases,

(4) a fluorescent is formed, and then

(5) the products are colored brown.

The mechanism of AGE production has been proposed by some groups. Forexample, the theory of Brownlee et al is shown below (Brownlee, M. etal., Science, 232, 1629 (1986)). ##STR4##

Maillard reaction is observed in healthy person, and particularly thisis caused notably in diabetics that a level of blood sugar is high andin protein of which metabolic turnover is slow.

For example, in the case of haemoglobin, the level of glycosylation indiabetic mouse are 2.7 times as high as that of normal mouse (Monnier,V.M. et al., The Maillard Reaction in Foods and Nutrition, ACS SymposiumSeries, 215, 432, Am. Chem. Soc., Washington, D.C. (1983)), andglycosylation of serum albumin in diabetics was advanced (Guthrow, C.E.et al., Proc. Natl. Acad. Sci. U.S., 76, 4258 (1979)).

Further, it was turned out that, when a glycosylated serum protein wasadministrated intravenously during 12 weeks, the typical diabetic renallesion was observed (Monnier, V.M. et al., Clin. Endocrinol. Metab., 11,431 (1982)).

Crystallin in lens is the special protein which is not metabolized atall after its biosynthesis. When crystallin was glycosylated, its stericstructure was transformed and the SH groups were enzymatically oxidizedto form S--S bond. A sequence of processes induced to polymerize theprotein in crystallin.

In the case of diabetic cataract in rats, the ratio of binding ofprotein and glucose was ten times as high as that of normal rat, andalso intramolecular S--S bond formation increased (Monnier, V. M. &Cerami, A., Clin. Endocrinol. Metab. 11, 431 (1982)).

Glycosylation of crystallin caused its polymerization, decrease in itssolubility, formation of fluorescent substance, and further yellow andbrown coloring. This phenomenon is very similar to that of lens by aging(Chiou, S. H., Chylack, L. T., Jr., Tung, W. H., & Bunn, F., J. Biol.Chem., 256, 5176 (1981)).

Collagen and elastin in connective tissue contain lysine andhydroxylysine abundantly, the speed of their metabolic turnover is slow,and the existance of reactants with glucose at the basement membrane ofrenal adrenal glands, skin and tendon has been found (Monnier, V. M.,Stevens, V. J., & Cerami, A., Maillard Reactions in Food, Prog. FoodNutr. Sci., 5, 315, Pergamon Press, London), further these glycosylationproducts might be related to sclerosis in a blood vessel wall(Rosenburg, H., Modrak, J. B., Hassing, J. M., Al-Turk, W. A., & Stohs,S. J., Biochem. Biophys. Res. Commun, 91 498 (1979)).

The cause of diabetic neurosis may be nonenzymatic glycosylation ofneuro-myelin protein (Monnier, V. M. et al., Clin. Endocrinol. Metab.,11, 431 (1982)).

In this way, Maillard reaction in a body is related to not only variousdiabetic complication but also a lot of diseases accompanied with aging.

Moreover, in recent research, it is reported that free radical relatesto glycosylation of protein. (diabete & Metabolism (Paris), 14, 25-30(1988)).

RELATED ARTS

On the above background, recently, researches of Maillard reactioninhibitors have been carried out. For example, Brownlee, M. et al.showed that aminoguanidine inhibits Maillard reaction in vitro, and thataminoguanidine, administered to diabetic rats, inhibits diabetes-inducedaccumulation of advanced glycosylation end products in arterial wallconnective tissue protein (Brownlee, M. et al., Science, 232, 1629(1986)).

They have considered that the amino group of a nucleophilic hydrazinecompound (i.e. the amino group which is bonded to guanidino group inaminoguanidine) blocks reactive carbonyls on early glycosylationproducts, and inhibits further cross-link formation of chemicallyreversible Amadori product.

Further, in the specification of Japanese Patent Kokai No. 62-142114,i.e. European Patent Publication No. 222313, it was suggested that thepharmaceutical composition comprising compound having the groupcontaining reactive nitrogen atoms, which enable to react with reactivecarbonyls in chemically reversible Amadori product, inhibits theproduction of advanced glycosylation end products. Concretely, thecompositions comprising aminoguanidine, α-hydrazinohistidine and lysineare disclosed.

And further, as the compounds which have an equal or similar structurewith those of this invention, the compounds of the formula as followsare suggested.

(1) In the specification of Japanese Patent Kokai No. 61-260077, i.e.European Patent Publication No. 202580, it is disclosed that thecompounds of the formula: ##STR5## (wherein R¹, R⁴ and R⁵ severallyrepresent a hydrogen atom or lower alkyl group, R² represents a hydrogenatom, halogen atom, hydroxy group, lower alkoxy group or loweralkenyloxy group, R³ represents a hydrogen atom, lower alkyl group orlower alkoxy group, X represents a methylene group or carbonyl group, Yrepresents a sulfur atom or imino group, n represents an integer of 0, 1or 2) are useful as anti-peptic ulcer agent.

(2) In the specification of Japanese Patent Kokai No. 62-169726, i.e.Derwent accession No. 87-246978/35, it is disclosed that the compoundsof the formula ##STR6## (wherein R¹ represents a hydrogen atom, R²represents a hydroxy group or guanidinocarbonyl group, n represents aninteger of 1 to 3.) are useful as 5-lipoxygenase inhibitor.

DISCLOSURE OF THE INVENTION

The present inventors have searched for the compounds, which possess asuperior inhibitory effect on Maillard reaction and high safety, andhave already filed patent applications for aminoguanidine derivatives(see European Patent Publication Nos. 325936 and 339496). And, accordingto recent research, the present inventors have found that the compoundsof the present invention which chroman skeletons are introduced intoaminoguanidine derivatives also accomplish the purpose. Moreover,according to next research, we have found that the compounds possess anantioxidation effect besides an inhibitory effect on Maillard reaction.

Accordingly, the present invention is related to:

1) benzopyran derivatives of the formula: ##STR7## wherein R^(1a) ishydrogen, C1-4 alkyl or C1-4 alkoxy; or two R^(1a) taken together with7th- and 8th-carbon to which they are attached form C6 carboxyclic ring;

R^(2a) is hydrogen, C1-4 alkyl or C1-4 alkoxy;

R^(3a) is hydrogen, C2-4 acyl or benzoyl;

na is 1-3;

Ya is C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene;

Ma is

i) bond or

ii) a group of the formula:--Da--Ba--;

Da is

i) --O-- or

ii) --S--;

Ba is

i) C1-4 alkylene or

ii) a group of the formula: ##STR8## Za is i) bond,

ii) --OCO--,

iii) --CONR^(9a) --,

iv) --COO--,

v) --NR^(9a) CO--,

vi) --O-- or

vii) --NH--CO--NH--;

Wa is a group of the formula: --W1a--Aa--W2a--;

Aa is

i) bond or

ii) a group of the formula: ##STR9## Ea is i) bond,

ii) --O-- or

iii) --S--; ○Ga is C4-10 carbocyclic or heterocyclic ring; or C4-10carbocyclic or heterocyclic ring substituted by one to three C1-4 alkyl,C1-4 alkoxy, halogen, a group of the formula: --COOR^(7a), trihalomethylor acetamido;

W1a and W2a each, independently, is

i) bond

ii) C1-4 alkylene,

iii) C2-4 alkenylene or

iv) C2-4 alkynylene;

R^(4a) is hydrogen or C1-4 alkyl;

R^(5a) is hydrogen, C1-4 alkyl or amino;

R^(6a) is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, a group of theformula: --COOR^(8a), trihalomethyl or acetoamido;

R^(7a) is hydrogen or C1-4 alkyl;

R^(8a) is hydrogen or C1-4 alkyl;

R^(9a) is hydrogen, C1-4 alkyl or benzyl;

with the proviso that:

i) Da is bonded to Ya and Ba is bonded to Za;

ii) Ea is bonded to W1a and ○Ga is bonded to W2a;

iii) a double or triple bond in alkenylene or alkynylene is not directlybonded to oxygen;

iv) when Aa represents ##STR10## W1a does not represent a bond; v) thefollowing compound is excluded:

wherein R1a attached to the 5th-carbon is hydrogen or C1-4 alkyl;

R^(1a) attached to the 7th-carbon is hydrogen, C1-4 alkyl or C1-4alkoxy;

R^(1a) attached to the 8th-carbon is hydrogen or C1-4 alkyl;

R^(2a) is methyl;

R^(3a) is hydrogen;

R^(4a) is hydrogen;

R^(5a) is hydrogen;

--Ya--Ma--Za--Wa-- is C1-3 straight-chain alkylene;

and the pharmaceutically acceptable acid addition salts thereof,

2) processes for the preparation of them,

3) inhibitory agents on Maillard reaction and antioxidants containing,as active ingredient, the compound of the formula: ##STR11## whereinR^(1b) is hydrogen, C1-4 alkyl or C1-4 alkoxy; or two R^(1b) takentogether with 7th- and 8th-carbon to which they are attached form C6carbocyclic ring;

R^(2b) is hydrogen, C1-4 alkyl or C1-4 alkoxy;

R^(3b) is hydrogen, C2-4 acyl or benzoyl;

nb is 1-3;

Yb is C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene;

Mb is

i) bond or

ii) a group of the formula: --Db--Bb--;

Db is

i) --O-- or

ii) --S--;

Bb is

i) C1-4 alkylene or

ii) a group of the formula: ##STR12## Zb is i) bond,

ii) --OCO--,

iii) --CONR^(9b) --,

iv) --COO--,

v) --NR^(9b) CO--,

vi) --O-- or

vii) --NH--CO--NH--;

Wb is a group of the formula: --W1b--Ab--W2b--;

Ab is

i) bond or

ii) a group of the formula: ##STR13## Eb is i) bond,

ii) --O-- or

iii) --S--;

○Gb is C4-10 carbocyclic or heterocyclic ring; or C4-10 carbocyclic orheterocyclic ring substituted by one to three C1-4 alkyl, C1-4 alkoxy,halogen, a group of the formula: --COOR^(7b), trihalomethyl oracetamido;

W1b and W2b each, independently, is

i) bond

ii) C1-4 alkylene,

iii) C2-4 alkenylene or

iv) C2-4 alkynylene;

R^(4b) is hydrogen or C1-4 alkyl;

R^(5b) is hydrogen, C1-4 alkyl or amino;

R^(6b) is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, a group of theformula: --COOR^(8b), trihalomethyl or acetoamido;

R^(7b) is hydrogen or C1-4 alkyl;

R^(8b) is hydrogen or C1-4 alkyl;

R^(9b) is hydrogen, C1-4 alkyl or benzyl;

with the proviso that:

i) Db is bonded to Yb and Bb is bonded to Zb;

ii) Eb is bonded to W1b and ○Gb is bonded to W2b;

iii) a double or triple bond in alkenylene or alkynylene is not directlybonded to oxygen;

iv) when Ab represents ##STR14## W1b does not represent a bond; or thepharmacutically acceptable acid addition salts thereof.

COMPARISON WITH RELATED ARTS

The compounds of the formula (IA), of the present invention are notdisclosed in the formulae (C) and (D), and therefore, are quite novel. Apart of the compounds of the formula (IB) has been already disclosed inthe formula (C). However, it is only described that the compounds of theformula (C) are useful as anti-peptic ulcer agents and the compounds ofthe formula (D) are useful as 5-lipoxygenase inhibitor. Thesedescription does not teach and suggest that the compounds of theformulae (IA) and (IB), of the present invention possess an inhibitoryeffect on Maillard reaction and antioxidation effect. Accordingly, thecompounds of the present invention are unobvious over the related arts.

The present invention includes all isomers unless otherwise specified.For example, alkyl group, alkoxy group, alkylene group and alkenylenegroup mean straight chain or branched-chain alkyl group, alkoxy group,alkylene group, and the double-bond in alkenylene group includes E, Zand mixture of E and Z. And, in case of existing branched-chain alkylgroup, the present invention includes the isomers caused by existingasymmetrical carbon atoms.

In the formulae (IA) and (IB), alkyl groups of from 1 to 4 carbonatom(s) shown by R^(1a), R^(1b), R^(2a), R^(2b), R^(4a), R^(4b), R^(5a),R^(5b), R^(6a), R^(6b), R^(7a), R^(7b), R^(8a), R^(8b), R^(9a), R^(9b)and substituents in ○Ga and ○Gb are methyl, ethyl, propyl, butyl groupand isomeric groups thereof. Alkoxy groups of from 1 to 4 carbon atom(s)shown by R^(1a), R^(1b), R^(2a), R^(2b), R^(6a), R^(6b) and substituentsin ○Ga and ○Gb are methoxy, ethoxy, propoxy, butoxy group and isomericgroups thereof. Every groups are preferable. C6 carbocyclic ring shownby the group which two R^(1a) and two R^(1b) represent together with7th- and 8th-carbon atoms are benzene ring and the rings which may bepartially or fully saturated thereof. Every rings are preferable. R.sup.1a, R^(1b), R^(2a), R^(2b), R^(4a), R^(4b), R^(7a), R^(7b), R^(8a) andR^(8b) also preferably represent a hydrogen atom. R^(9a) and R^(9b) alsopreferably represent a hydrogen atom or benzyl.

In the formulae (IA) and (IB), acyl groups of from 2 to 4 carbon atomsshown by R3a and R3b are acetyl, propionyl, butyryl group and isomericgroups thereof. Every group are preferable. R^(3a) and R^(3b) are alsopreferable to represent a hydrogen atom and benzoyl group. R^(5a) andR^(5b) are also preferable to a hydrogen atom or amino group.

In the formulae (lA) and (lB), alkylene groups of from 1 to 7 carbonatoms shown by Ya and Yb are methylene, ethylene, trimethylene,tetramethylene, pentamethylene, hexamethylene, heptamethylene group andisomeric groups thereof. Every groups are preferable. Alkylene group offrom 1 to 4 carbon atom(s) shown by Ba, Bb, W1a, W1b, W2a and W2b aremethylene, ethylene, trimethylene, tetramethylene group and isomericgroups thereof.

In the general formulae (lA) and (lB), alkenylene groups of from 2 to 7carbon atoms shown by Ya and Yb are the groups which contain one or twodouble bond(s) in ethylene, trimethylene, tetramethylene,pentamethylene, hexamethylene, heptamethylene group and isomeric groupthereof. Alkenylene groups of from 2 to 4 carbon atoms shown by W1a,W1b, W2a and W2b are the groups which contain one or two double bond(s)in ethylene, trimethylene, tetramethylene group and isomeric groupthereof, preferably, vinylene, propenylene, 1-butenylene.

In the formulae (lA) and (lB), alkynylene group of from 2 to 7 carbonatoms shown by Ya and Yb, are the groups which contain one or two triplebond(s) in ethylene, trimethylene, tetramethylene, pentamethylene,hexamethylene, heptamethylene and isomeric group thereof. Alkynylenegroup of from 2 to 4 carbon atoms shown by W1a, W1b, W2a and W2b are thegroups which contain one or two triple bond(s) in ethylene,trimethylene, tetramethylene group and isomeric group thereof,preferably ethynylene, propynylene, 1-butynylene group and isomericgroup thereof.

In the formulae (lA) and (lB), trihalomethyl group shown by R^(6a),R^(6b), substituents in ○Ga and ○Gb are trifluoromethyl,trichloromethyl, tribromomethyl, triiodomethyl group. Halogen atom shownby R^(6a), R^(6b), substituents in ○Ga and ○Gb are fluorine, chlorine,bromine and iodine atom. Every group are preferable. R^(6a) and R^(6b)also preferably represent a hydrogen atom and acetamido group.Substituents in ○Ga and ○Gb also preferably represent acetamido group.○Ga and ○Gb also preferably represent unsubstituted carbocyclic orheterocyclic ring.

In the formulae (IA) and (IB), carbocyclic ring of from 4 to 10 carbonatoms shown by ○Ga and ○Gb are mono- or bi-aromatic ring. This ringsare, for example, benzene, pentalene, indene, naphthalene, azulene ringwhich may be partially or fully saturated.

Preferable rings are benzene, naphthalene ring and cycloalkane ring offrom 4 to 7 carbon atoms. More preferable rings are benzene ring andcyclohexane ring.

In the formulae (IA) and (IB), heterocyclic ring of from 4 to 10 carbonatoms shown by ○Ga and ○Gb are mono- or bi-heterocyclic rings which maybe partially or fully saturated. For example, they are furan, thiophene,pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole,furazan, pyridine, pyridazine, pyrimidine, pyrazine, indole, isoindole,benzofuran, benzothiophene, indolizine, chromene, quinoline,isoquinoline, quinolizine, purine, indazole, quinazoline, cinnoline,quinoxaline, phthalazine, pteridine rings and partially or fullysaturated rings thereof.

Aa, Ab, W1a, W1b, W2a and W2b also preferably represent a bond.

The compounds of the formulae (IA) and (IB), if desired, may beconverted into acid addition salts by the known methods. Preferably,acid addition salts are non-toxic salts and water-soluble. The suitableacid addition salts are, for example, hydrochloric acid, hydrobromicacid, hydroiodic acid, sulfuric acid, phosphoric acid, an inorganic acidsuch as nitric acid, or an organic acid such as acetic acid, lacticacid, tartric acid, benzoic acid, citric acid, methanesulphonic acid,ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid,isethionic acid, glucuronic acid and gluconic acid. Acid addition saltsmay be obtained by the known methods, for example, by reactingstoichiometric quantities of a compound of formula (IA) or (IB) and theappropriate acid in a suitable solvent.

PROCESS FOR THE PREPARATION OF THE COMPOUNDS OF THE PRESENT INVENTION

The compounds of the formula (IA), of the present invention may beprepared by the methods described hereinafter. Moreover the compounds ofthe formula (IB), of the present invention may be prepared by themethods as described for those of the formula (IA). ##STR15## (whereinR^(55a) is hydrogen or C1-4 alkyl; X is chlorine, bromine and iodine;and the other symbols are the same meanings described hereinbefore.)

Step 1 may be carried out, for example, in an inert organic solvent(ethanol, methanol etc.).

Step 2 may be carried out, for example, by reacting with methyl halide(methyl iodide etc.) followed by hydrazine in an inert organic solvent(ethanol, methanol etc.).

Step 3 is the reaction to form amido bond. For example, it may becarried out by reacting:

(i) in an inert organic solvent (methylene chloride, toluene etc.),using dicyclohexylcarbodiimide (DCC) or 2-chloro-1-methylpyridiniumiodide or a tertiary amine (triethylamine etc.) at a temperature of from0° C. to 50° C.,

(ii) acid chloride corresponding to acid of the formula (V) with desiredamine of the formula (IV) at a temperature of from -10° C. to 40° C. or

(iii) acid of the formula (V) with oxalyl chloride followed by desiredamine of the formula (IV) at a temperature of from -20° C. to 0° C. inan inert organic solvent (dimethylformamide (DMF)).

Step 4 are esterification. For example, it may be carried out byreacting:

(i) in an inert organic solvent (DMF etc.) in the presence of DCC or atertiary amine (pyridine, triethylamine etc.), at a temperature of from0° C. to 50° C.,

(ii) acid chloride corresponding to acid of the formula (VII) withdesired alcohol of the formula (VI) in an inert organic solvent (DMFetc.), at a temperature of from -10° C. to 40° C.,

(iii) acid of the formula (VII) with oxalyl chloride followed by desiredalcohol of the formula (VI) at a temperature of from -20° C. to 0° C. inan inert organic solvent (DMF etc.).

STARTING MATERIAL

The starting materials and each reagents of the formulae (II), (III),(IV), (V), (VI) and (VII) are known or may be prepared by the stepsshown in scheme 1 to 12 described hereinafter.

Namely, among the compounds of the formula (II),

(II)-1: the compounds (II)-1, wherein Ma and Za are bond and Wa is bond,C1-8 alkylene, C2-8 alkenylene or alkynylene, are known or may beprepared with using known compounds by known methods and

(II)-2: the compounds (II)-2, wherein Za is --OCO--, may be prepared bythe steps shown in scheme 1. ##STR16## (II)-3: The compounds (II)-3,wherein Za is --NR^(9a) CO--, may be prepared by the steps shown inscheme 2. ##STR17## (II)-4: The compounds (II)-4, wherein Za is --COO--,may be prepared by the steps shwon in scheme 3. ##STR18## (II)-5: Thecompounds (II)-5, wherein Za is --CONR^(9a) --, may be prepared by thesteps shown in scheme 4. ##STR19## (II)-6: The compounds (II)-6, whereinZa is --O--, may be prepared by the steps shown in scheme 5 and 6.##STR20## (II)-7: The compounds (II)-7, wherein Za is --NHCONH--, may beprepared by the steps shown in scheme 7-1. ##STR21## (II)-8: Thecompounds (II)-8, wherein Za is bond; Ma is a group of the formula:--Da--Ba--; and Aa is a group of the formula: ##STR22## may be preparedby the steps shown in scheme 7-2. ##STR23##

The compounds of the formula (III) may be prepared from the compounds ofthe formula (II) by the steps shown in scheme 8. ##STR24##

Among the compounds of the formula (IV),

(IV)-1: the compounds (IV)-1a, wherein Ma is bond and R^(9a) ishydrogen, are known or may be prepared with using known compounds byknown methods and the compounds (IV)-1b, wherein Ma is bond and R^(9a)is C1-4 alkyl or benzyl, may be prepared by the steps shown in scheme9-1. ##STR25## (IV)-2: The compounds (IV)-2, Ma is a group of theformula: --Da--Ba--, may be prepared by the steps shown in scheme 9-2.##STR26##

The compounds of the formula (V) are known or may be prepared with usingknown compounds by known methods.

Among the compounds of the formula (VI),

(VI)-1: the compounds (VI)-1, wherein Ma is bond, are known or may beprepared with using known compounds by known methods.

(VI)-2: the compounds (VI)-2, wherein Ma is a group of the formula:--Da--Ba--, are prepared by the steps shown in scheme 10. ##STR27##

The compounds of the formula (VII) are known or may be prepared withusing known compounds by known methods.

Among the compounds of the formula (VIII),

(VIII)-1: The compounds (VIII)-1, wherein Ma is bond, are known or maybe prepared with using known compounds by known methods and

(VIII)-2: the compounds (VIII)-2, wherein Ma is a group of the formula:--Da--Ba--, may be prepared with using CH₃ OCH₂ Cl instead of R^(33a) Clused as acylation reagent.

The compounds of the formula (IX) are known or may be prepared withusing known compounds by known methods.

Among the compounds of the formula (X),

(X)-1: the compounds (X)-1, wherein Ma is bond, are known or may beprepared with using known compounds by known methods and

(X)-2 the compounds (X)-2, wherein Ma is a group of the formula:--Da--Ba--, may be prepared by the steps shown in scheme 11. ##STR28##

Among the compounds of the formula (XI),

(XI)-1: the compounds (XI)-1, wherein Ma is bond, are known or may beprepared with using known compounds by known methods and

(XI)-2: the compounds (XI)-2, wherein Ma is a group of the formula:--Da--Ba--, may be prepared by the steps shown in scheme 12. ##STR29##

The compounds of the formulae (XII), (XIII), (XIV), (XV), (XVI) and(XVII) are known or may be prepared with using known compounds by knownmethods.

In the scheme 1 to 12 described hereinbefore,

R^(33a) is C2-4 acyl or benzoyl;

R^(44a) is C1-4 alkyl;

R³¹ O is hydroxy or methoxymethoxy;

MOMO is methoxymethoxy;

p-TsCl is p-toluenesulfonyl chloride;

T is tosyl;

R⁷⁷ is methyl or ethyl;

Aaa is

i) bond or

ii) a group of the formula: ##STR30## Eaa is i) bond,

ii) --O--or

iii) --S--;

Gaa is C4-10 carbocyclic or heterocyclic ring; or C4-10 carbocylic orheterocyclic ring subsituted by one to three C1-4 alkyl, C1-4 alkoxy,halogen, trihalomethyl or acetamideo;

DEAD is diethyl azodicarboxylate; and

the other symbols are the same meanings described hereinbefore.

The reaction products may be purified by conventional methods, forexample, distillation at atmospheric or reduced pressure, highperformance liquid chromatography, thin layer chromatography or columnchromatography using silica gel or magnesium silicate or washing orrecrystallization. Purification may be carried out after each reactionsor a series of reactions.

EFFECT

The inhibitory activity on Maillard reaction of the compounds of thepresent invention has confirmed by the screening system mentioned below.

(1) Method of experiment

Lysozyme (10 mg/ml) and fructose (100 mM) were dissolved in 0.2M sodiumphosphatic buffer solution (PH 7.4). The solution was incubated at atemperature of 37° C. for 3 days. A given volume of the reactionsolution was separated using SDS-PAGE by the electrophoresis. After theelectrophoresis, the SDS-PAGE was dyed by 0.2% Coomassie Brilliant BlueR-250 and then the dimer was determined by densitometer.

The compounds of the present invention were added before incubation andthe inhibitory activity of them against the formation of the dimer wasexamined in various concentrations and IC₅₀ values were calculated.

(2) The results are shown in the following table 1.

                  TABLE 1                                                         ______________________________________                                        Ex. No.      IC.sub.50 value (mM)                                             ______________________________________                                        1         (a)    0.20                                                         1         (d)    0.34                                                         1         (e)    0.050                                                        1         (h)    0.053                                                        1         (i)    0.10                                                         1         (j)    0.060                                                        1         (m)    0.44                                                         2                0.45                                                         2         (e)    0.19                                                         2         (f)    0.15                                                         3                0.36                                                         4                0.15                                                         5                0.32                                                         5         (b)    0.074                                                        5         (c)    0.50                                                         5         (f)    0.022                                                        7         (a)    0.20                                                         7         (b)    0.012                                                        7         (c)    0.0048                                                       7         (d)    0.048                                                        7         (e)    0.030                                                        7         (f)    0.018                                                        7         (h)    0.019                                                        7         (k)    0.012                                                        7         (l)    0.054                                                        7         (m)    0.012                                                        7         (n)    0.010                                                        7         (t)    0.017                                                        8                0.30                                                         9                0.0062                                                       9         (a)    0.010                                                        9         (d)    0.0054                                                       9         (j)    0.0048                                                       9         (l)    0.0066                                                       9         (m)    0.009                                                        10               0.075                                                        10        (a)    0.021                                                        10        (e)    0.036                                                        12               0.20                                                         14               0.22                                                         15               0.22                                                         17               0.013                                                        19               0.056                                                        21               0.22                                                         22               0.048                                                        22        (a)    0.50                                                         23               0.13                                                         24               0.18                                                         24        (a)    0.068                                                        26               0.27                                                         27               0.0058                                                       27        (b)    0.19                                                         27        (f)    0.0056                                                       28        (c)    0.0042                                                       29               0.0075                                                       29        (a)    0.020                                                        ______________________________________                                    

The antioxiding effect of the compounds of the present invention hasconfirmed by the screening system which examines inhibitory activityagainst formation of peroxidized fat mentioned below.

(1) Method of experiment

Male Sprague Dawley rat was fasted for 12 hrs (overnight) beforeexperiments, and was anesthetized with ether. Rat liver was perfusedwith ice-cold 0.9% NaCl via the portal vein, and promptly excised. 10%Liver homogenates were prepared in ice-cold 1.15% KCl. The reaction wasstarted by adding 200 μM FeCl₂ to the liver homogenate (0.2 μl), andincubated at 37° C. for 1 hr. Lipid peroxide was measured by the TBAmethod according to the method of Ohkawa (See Analytical Biochemistry,95, 351 (1979)).

The compounds of the present invention were added before incubation. Andthe efficacy thereof was examined and calculated IC₅₀ values thereof.

(2) The results are shown in the following Table 2.

                  TABLE 2                                                         ______________________________________                                        Ex. No.      IC.sub.50 value (μM)                                          ______________________________________                                        1                0.60                                                         1         (a)    0.54                                                         1         (b)    0.78                                                         1         (c)    0.80                                                         1         (e)    0.16                                                         1         (f)    0.82                                                         1         (g)    0.90                                                         1         (h)    0.90                                                         1         (j)    0.46                                                         1         (k)    0.44                                                         1         (l)    0.38                                                         1         (m)    0.60                                                         2                0.66                                                         2         (a)    0.78                                                         2         (b)    0.47                                                         2         (c)    0.50                                                         3                0.54                                                         ______________________________________                                    

The results in the Table 1 and Table 2 show that the compounds of thepresent invention and acid addition salts thereof possess an inhibitoryeffect on Maillard reaction and an antioxiding effect.

The compounds of the formulae (IA) and (IB), of the present invention,and pharmaceutically acceptable acid addition salts thereof possess theinhibitory activity on Maillard reaction. Accordingly, the compounds ofthe present invention are useful for treatment and/or prevention ofseveral diabetic complication, i.e. coronary heart disease, peripheralcirculatory insufficiency or failure, cerebrovascular hindrance,neurogenous diabetes, nephropathy, arteriosclerosis, arthrosclerosis,cataracta and retinopathy, and the diseases induced by aging, i.e.atherosclerosis, senile cataract and cancer.

Moreover, the compounds of the formulae (IA) and (IB), of the presentinvention and pharmaceutically acceptable acid addition salts thereofpossess an antioxidizing effect, that is, an inhibitory effect onreaction by free radical. Accordingly, the compounds are useful fortreatment and/or prevention of several diseases caused by formation ofperoxidized fat, i.e. arteriosclerosis, glycosuria, myocardialinfarction, peripheral circulatory disorders, cerebrovascular disease,cancer, inflammation, digestive diseases and aging.

TOXICITY

It was confirmed that the toxicity of the compounds of the presentinvention were very low. Accordingly, it was confirmed that thecompounds of the present invention were useful for prevention and/ortreatment for deseases attributed to Maillard reaction, in animalsincluding human beings, especially human beings.

ADMINISTRATION

For the purpose above described, the compounds of the present inventionof the formulae (IA) and (IB) and pharmaceutically acceptable acidaddition salts thereof may be normally administered systemically orpartically, usually by oral or parenteral administration.

The doses to be administered are determined depending upon age, bodyweight, symptom, the desired therapeutic effect, the route ofadministration, and the duration of the treatment etc. In the humanadult, the doses per person per dose are generally between 1 mg and 1000mg, by oral administration up to several times per day, and aregenerally between 0.1 mg and 100 mg, by parenteral administration(preferably, intravenous administration) up to several times per day.

As mentioned above, the doses to be used depend upon various conditions.Therefore, there are cases in which doses lower than or greater than theranges specified above may be used.

In administration of the compounds of the present invention, solidcomposition, liquid composition and other composition are used for oraladministration, and injections, medicines for external use andsuppositories are used for parenteral administration.

Solid compositions for oral administration include compressed tablets,pills, capsules, dispersible powders, and granules. Capsules containhard capsules and soft capsules.

In such compositions, one or more of the active compound(s) is or are,admixed with at least one inert diluent (lactose, mannitol, glucose,hydroxypropyl cellulose, microcrystalline cellulose, starch,polyvinylpyrrolidone, magnesium metasilicate aluminate etc.). Thecompositions may also comprise, as is normal practice, additionalsubstances other than inert diluents: e.g. lubricating agents (magnesiumstearate etc.), disintegrating agents (cellulose calcium glycolateetc.), stabilizing agent (lactose etc.), and assisting agent fordissolving (glutamic acid, asparaginic acid etc.).

The tablets or pills may, if desired, be coated with film of gastric orenteric material (sugar, gelatin, hydroxypropyl cellulose orhydroxypropylmethyl cellulose phthalate etc.), or be coated with morethan two films. And further, it may be include capsules of absorbablematerials such as gelatin.

Liquid compositions for oral administration includepharmaceutically-acceptable solutions, emulsions, suspensions, syrupsand elixirs.

In such compositions, one or more of the active compound(s) is or arecomprise in inert diluent(s) commonly used in the art (purified water,ethanol etc.).

Besides inert diluents, such compositions may also comprise adjuvants(wetting agents, suspending agent etc.), sweetening agents, flavouringagents, perfuming agents and preserving agent.

Other compositions for oral administration include spray compositionswhich may be prepared by known methods and which comprise one or more ofthe active compound(s).

Spray compositions may comprise additional substances other than inertdiluents: e.g. stabilizing agents (sodium sulfite etc.), isotonic buffer(sodium chloride, sodium citrate, citric acid etc.)

For preparation of such spray compositions, for example, the methoddescribed in the U.S. Pat. Nos. 2,868,691 or 3,095,355 may be used.

Injections for parenteral administration include sterile aqueous ornon-aqueous solutions, suspensions and emulsions. In such compositions,one more of active compound(s) is or are admixed at least one of inertaqueous diluent(s) (distilled water for injection, physiological saltsolution etc.) or inert non-aqueous diluent(s) (propylene glycol,polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80 (registeredtrade mark) etc.).

Injections may comprise additional other than inert diluents: e.g.preserving agents, wetting agents, emulsifying agents, dispersingagents, stabilizing agent (lactose etc.), assisting agents such asassisting agents for dissolving (glutamic acid, asparaginic acid etc.).

They may be sterilized for example, by filtration through abacteria-retaining filter, by incorporation of sterilizing agents in thecompositions or by irradiation. They also be manufactures in the form ofsterile solid compositions, for example, by freeze-drying, and which canbe dissolved in sterile water or some other sterile diluents forinjection immediately before used.

Other compositions for parenteral administration include liquids forexternal use, and endermic liniments (ointment etc.), suppositories andpessaries which comprise one or more of the active compound(s) and maybe prepared by known methods.

REFERENCE EXAMPLE AND EXAMPLE

The following reference examples and examples illustrate the compoundsof the present invention and the process for the preparation of them,but not limit the present invention.

The solvents in the parentheses show the developing or eluting solventsand the rations of the solvents used are by volume in chromatographicseparations. "IR" were measured by KBr tablet method.

REFERENCE EXAMPLE 12-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethanol##STR31##

Lithium aluminum hydride (LAH) (8.0 g) was suspended in ether (500 ml).A solution of methyl2-(6-acetoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)acetate(12.16 g) in ether (200 ml) was added dropwise to the suspension. Themixture was stirred for 1 hour. A saturated aqueous solution of sodiumsulfate was added dropwise to the reaction solution at room temperatureto decompose excess LAH. The solution was filtered. The filtrate wasevaporated to give the title compound (9.31 g) having the followingphysical data.

TLC (ethyl acetate:hexane=2:1): Rf 0.43.

REFERENCE EXAMPLE 2N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]phthalimide##STR32##

Diethyl azodicarboxylate (3.36 ml) was added dropwise to a solution ofthe alcohol (prepared in reference example 1, 4.69 g) and phthalimide(3.14 g) in anhydrous tetrahydrofuran (80 ml) at a temperature of 0° C.The temperature of the solution was raised to room temperature. Thesolution was stirred at 2 hours. Water was added to the solution. Thesolution was extracted with ethyl acetate. The extract was washed with asaturated brine, dried over magnesium sulfate and then evaporated. Theresidue was purified by column chromatography on silica gel(hexane:ethyl acetate=3:1) to give the title compound (6.8 g) having thefollowing physical data.

TLC (ethyl acetate:hexane=2:1): Rf 0.54.

REFERENCE EXAMPLE 32-(2-aminoethyl)-2,5,7,8-tetramethyl-6-hydroxy-3,4-dihydro-2H-benzo[1,2-b]pyran##STR33##

Imide (prepared in reference example 2, 450 mg) was suspended in ethanol(7 ml). 80% hydrazine hydride (1 ml) was added dropwise to thesuspension at room temperature. The mixture was stirred for 1 hour.

The reaction solution was evaporated. Ethyl acetate was added to theresidue. The solution was filtered to remove white crystal precipitated.The filtrate was evaporated. The residue was purified by columnchromatography on silica gel (methylene chloride:ethanol=15:1→10:1) togive the title compound (220 mg) having the following physical data.

TLC (ethyl acetate:acetic acid:water=3:1:1): Rf 0.51.

REFERENCE EXAMPLE 41-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-3-benzoylthiourea##STR34##

A solution of benzoylisothiocyanate (28.0 g) in acetone (200 ml) wasadded dropwise to a solution of amine (prepared in reference example 3,34.3 g) in acetone (800 ml). The solution was stirred for 15 hours atroom temperature. The reaction solution was evaporated. The residue waspurified by column chromatography on silica gel (hexane:ethylacetate=10:1→4:1→2:1) to give the title compound (32.0 g) having thefollowing physical data.

TLC (n-hexane:ethyl acetate=4:1): Rf 0.23.

REFERENCE EXAMPLE 51-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]thiourea##STR35##

The thiourea compound (prepared in reference example 4, 32.0 g) wasdissolved in ethanol (310 ml). A 2N aqueous solution of sodium hydroxide(155 ml) was added to the solution. The mixture was stirred for 1 hourat room temperature and then for 1 hour at a temperature of 50° C. onwater bath. After confirmation of conclusion of the reaction, thereaction solution was diluted with water. The solution was extractedwith ethyl acetate (1 liter) followed by ethyl acetate (200 ml×5). Theextract was washed with water two times followed by a saturated brine,dried over magnesium sulfate and then evaporated. The residue waspurified by column chromatography on silica gel(chloroform:methanol=98:2→95:5) to give the title compound (17.4 g)having the following physical data.

TLC (chloroform:methanol=9:1): Rf 0.29.

REFERENCE EXAMPLE 62-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl4-hydroxymethylbenzyl ether ##STR36##

Alcohol (prepared in reference example 1, 1.25 g) was dissolved indimethylformamide (20 ml). 62% Sodium hydride (0.24 g) was added to thesolution. The solution was stirred for 1 hour at room temperature. Asolution of methyl 4-bromomethylbenzoate (1.14 g) in dimethylformamide(10 ml) was added to the solution. The solution was stirred for 15 hoursat room temperature. The reaction solution was stirred for 1.5 hours ata temperature of 60° C. Water was added to the reaction solution. Thesolution was extracted with ethyl acetate. The extract was washed with asaturated brine, dried over magnesium sulfate and evaporated. Theresidue was dissolved in ether (10 ml). The solution was reacted by thesame procedure as reference example 1. The residue was purified bycolumn chromatography on silica gel (n-hexane:ethyl acetate=2:1) to givethe title compound (147 mg) having the following physical data.

TLC (n-hexane:ethyl acetate=1:1): Rf 0.63.

REFERENCE EXAMPLE 72(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethanol##STR37##

A solution of alcohol (prepared in reference example 1, 130 g) indimethylformamide (1.2 liters) was added to sodium hydride 21.2 g) withcooling in an ice-bath. The solution was stirred for 40 mins at roomtemperature. The solution was cooled in an ice-bath once more.Chloromethyl methyl ether (40 ml) was added to the cooled solution. Thesolution was stirred for 25 mins at room temperature. Moreover,chloromethyl methyl ether (3.0 ml) was added to the solution. Thesolution was stirred for 5 mins and then poured into water (1.5 liters).The mixture was extracted with a mixed solution (1 liter) of n-hexaneand ether (1:1). The extract was washed with water, followed by a brineand dried over magnesium sulfate and then evaporated to give the residue(158.9 g) contained the title compound having the following physicaldata. The residue was used in next reaction without purification. TLC(ethyl acetate:n-hexane=2:3): Rf 0.29.

REFERENCE EXAMPLE 8 4-nitrophenyl2-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether ##STR38##

A solution of the residue (158.9 g) contained the methoxymethoxycompound, prepared in reference example 7 in dimethyl sulfoxide (1.1liter) was added to sodium hydride (20.8 g). The mixture was vigorouslystirred at 60° C. for one hour and then cooled. p-Chloronitrobenzene(81.8 g) was added to the mixture. The mixture was stirred at roomtemperature for 2 hours. The reaction mixture was poured into a mixtureof ice (500 g) and water (1.5 liters). The mixture was extracted with amixture solution (1 liter) of n-hexane-ether (1:1). The extract waswashed with water, followed by brine, dried over mangesium sulfate andthen evaporated. The residue was purified by column chromatography onsilica gel (ethyl acetate: n-hexane=1:9→1:4→2:3) to give the titlecompound (157.3 g) having the following physical data.

TLC (ethyl acetate: n-hexane=2:3): Rf 0.56; MS: m/e 415, 385, 370, 354,231.

REFERENCE EXAMPLE 9

4-nitrophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether ##STR39##

10% Sulfuric acid (38 g) was added to a solution of the ether (157.3 g)prepared in reference example 8 in acetic acid (600 ml). The solutionwas stirred at 60° C. for 20 minutes. The reaction mixture was cooled,poured into a mixture of sodium bicarbonate (1 kg) and ice (1 kg) andthen left until foaming finished. The mixture was extracted with ethylacetate (1 liter×2). The extract was washed with water, followed bybrine, dried over magnesium sulfate and then evaporated to give theresidue (142.7 g) contained the title compound having the followingphysical data. The residue was used in next reaction withoutpurification.

TLC (ethyl acetate:n-hexane=2:3):Rf 0.45; MS: m/e 371, 232, 165.

REFERENCE EXAMPLE 10 4-aminophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether ##STR40##

A solution of the residue (142.7 g) contained the ether compound,prepared in reference example 9 in a mixture solution of ethanol (900ml) and ethyl acetate (150 ml) was added to 10% palladium-carbon (15 g).Addition of hydrogen gas to the solution was carried out all night.Catalyst was removed from the reaction mixture by filtration. Thefiltrate was evaporated. The residue was purified by columnchromatography on silica gel (ethyl acetate:n-hexane=2:3) to give thetitle compound (120.6 g) having the following physical data.

TLC (ethyl acetate:n-hexane=2:3):Rf 0.17; MS: m/e 341, 233, 205, 165.

REFERENCE EXAMPLE 112-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)acetoaldehyde##STR41##

Oxalic chloride (2.27 ml) was dissolved in methylene chloride (30 ml).The solution was cooled to -60° C. A mixture of dimethylsulfoxide (3.69ml) and methylene chloride (5 ml) was slowly added dropwise to thesolution. The mixture was stirred for 20 mins. A solution of alcohol(5.1 g) prepared in reference example 7 in methylene chloride (5 ml) wasadded to the mixture. The reaction mixture was stirred at -60° C. for 50mins. Triethylamine (12 ml) was added to the reaction mixture. Thereaction mixture was taken out from a cooling bath. After 5 mins, waterwas added to the reaction mixture. The mixture was diluted with ethyhlacetate. The diluted mixture was washed in order with water, INhydrochloric acid, a saturated aqueous solution of sodium bicarbonateand brine and then dried over magnesium sulfate. The solution wasevaporated. The residue was purified by column chromatography on silicagel (n-hexane:ethyl acetate=4:1) to give the title compound (5.0 g)having the following physical data. TLC (n-hexane:ethyl acetate=4:1) Rf0.46.

REFERENCE EXAMPLE 12 Methyl4-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)-2-butenoate##STR42##

The aldehyde (5 g) prepared in reference example 11 was dissolved inbenzene (40 ml). Methyl (triphenylphosphoranylidene)acetate (8.57 g) wasadded to this solution. The mixture was stirred at 80° C. for one hour.The reaction solution was evaporated. The residue was purified by columnchromatography on silica gel (benzene:ethyl acetate=9:1) to give thetitle compound (5.6 g) having the following physical data.

TLC (n-hexane:ethyl acetate=4:1):Rf 0.43; MS: m/e 348, 317, 303, 271,249.

REFERENCE EXAMPLE 13 Methyl4-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydrio-2H-benzo[1,2-b]pyran-2-yl)butylate##STR43##

The ester (5.6 g) prepared in reference example 12 was dissolved inethanol (40 ml). 5% Palladium carbon (1.5 g) was added to this solution.The mixture was stirred under an atmosphere of hydrogen for one hour.The catalyst was removed from the reaction solution with using a celite.The reaction solution was evaporated to give the residue (5.6 g)contained the title compound having the following physical data. Theresidue was used in next reaction without purification.

TLC (n-hexane: ethyl acetate=4:1): Rf 0.55;

MS: m/e 350, 319, 305, 273.

REFERENCE EXAMPLE 141-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-3-(3-nitrophenyl)urea##STR44##

The amine (400 mg) prepared in reference example 3 was dissolved inanhydrous tetrahydrofuran (5 ml). A solution of 3-nitrophenylisocyanate(263 mg) in anhydrous tetrahydrofuran (1 ml) was added to the solution.The solution was stirred for 30 mins and then evaporated. The residuewas diluted with ethyl acetate. The solution was washed with a saturatedaqueous solution of sodium bicarbonate, 1N hydrochloric acid, followedby water, dried over magnesium sulfate and evaporated. The residue waspurified by column chromatography on silica gel (n-hexane: ethylacetate=1: 1) to give the title compound (650 mg) having the followingphysical data.

TLC (benzene: ethyl acetate=2: 1): Rf 0.45; MS: m/e 413, 275, 249, 232,220, 165.

REFERENCE EXAMPLE 154-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butyricacid ##STR45##

A 2N aqueous solution of sodium hydroxide (2.3 ml) was added to asolution of the methyl ester (800 mg), which was obtained with using thealcohol prepared in reference example 7 by the same procedure in orderas reference example 11→reference example 12→reference example 13, indimethoxy ethylene (20 ml). The solution was stirred at 50° C. allnight. The reaction solution was left alone for a moment and cooled inan ice-bath. 2N hydrochloric acid (2.5 ml) was added to the cooledsolution. The solution was extracted with ethyl acetate (60 ml). Theextract was washed with water, next brine, dried over anhydrousmagnesium sulfate and evaporated to give the title compound (763 mg)having the following physical data.

TLC (methanol: methylene chloride=1: 19): Rf 0.26; MS: m/e 336, 305,292, 291, 273.

REFERENCE EXAMPLE 16N-(3-nitrophenyl)-4-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylamide##STR46##

Triethylamine (0.17 ml) was added to a solution of the carboxylic acid(342 mg) prepared in reference example 15 in tetrahydrofuran (4 ml). Thesolution was cooled in an ice-bath. Ethyl chloroformate (0.11 ml) wasadded dropwise to the cooled solution. The solution was stirred for 2mins. A solution of m-nitroaniline hydrochloride (177 mg) in a mixedsolution of dimethylformamide (4 ml)-tetrahydrofuran (3 ml), whichtriethylamine (0.17 ml) was added to, was added dropwise to the stirredsolution of the carboxylic acid. The mixture was stirred for 30 mins andmoreover stirred at room temperature all night. The mixture was dilutedwith ether (60 ml). The diluted solution was washed in order with water,1N hydrochloric acid, a saturated aqueous solution of sodiumbicarbonate, water and brine, dried over anhydrous magnesium sulfate andevaporated. The residue was purified by column chromatography on silicagel (ethyl acetate:n-hexane=1:4→2:3) to give the title compound (188 mg)having the following physical data.

TLC (ethyl acetate: n-hexane=2:3): Rf 0.34; MS: m/e 456, 426, 411, 395,273, 255, 245, 231.

REFERENCE EXAMPLE 17N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-3-ethoxycarbonyl-5-nitrobenzamine##STR47##

Oxalyl chloride (6.65 ml) was added dropwise to a mixture ofdimethylformamide (70 ml) and methylene chloride (70 ml) cooled by amixture of dry ice and methanol. The mixture was stirred for 25 minswith cooling. A solution of 3-ethoxycarbonyl-5-nitrobenzoic acid (18.2g) in dimethylformamide (70 ml) was added dropwise to the mixture withcooling. The mixture was stirred at room temperature for one hour. Asolution of the amine (20 g) prepared in reference example 3 in a mixedsolution of dimethylformamide (150 ml) and methylene chloride (20 ml)was cooled by a mixture of dry ice and methanol.N,N-diisopropylethylamine (76 ml) was added to the cooled solution. Themixture prepared beforehand was added dropwise to the solution. Themixture was stirred at room temperature for 25 mins and then evaporated.The residue was diluted with ethyl acetate (600 ml). The dilutedsolution was washed with water and then brine, dried over anhydrousmagnesium sulfate and evaporated. The residue was purified by columnchromatography on silica gel (ethyl acetate: n-hexane=2:3) to give thetitle compound (28.4 g) having the following physical data.

TLC (ethyl acetate: benzene=1; 4): Rf 0.30; MS: m/e 470, 222.

REFERENCE EXAMPLE 182-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylp-toluenesulfonate ##STR48##

The alcohol (500 mg) prepared in reference example 7 was dissolved inpyridine (1.37 ml). The solution was cooled in an ice-bath.p-Toluenesulfonyl chloride (389 mg) was added to the cooled solution.The solution was taken out from an ice-bath and stirred at roomtemperature for 3 hours and then diluted with ethyl acetate. The dilutedsolution was washed with a saturated aqueous solution of cupric sulfateand then water, dried over anhydrous magnesium sulfate and thenevaporated. The residue was purified by column chromatography on silicagel (n-hexane: ethyl acetate=4:1) to give the title compound (740 mg)having the following physical data.

TLC (n-hexane: ethyl acetate=2:1): Rf 0.57.

REFERENCE EXAMPLE 19 2-ethoxycarbonyl-4-nitrophenyl2-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether ##STR49##

Anhydrous tetrahydrofuran (1 ml) and anhydrous hexamethylphosphoramide(1 ml) were added to ethyl 5-nitrosalicylate (100 mg). Sodium hydride(content 62.4%, 20 mg) was added to the mixture. The mixture was stirredfor 20 mins. A solution of the tosylate (213 mg) prepared in referenceexample 18 in anhydrous tetrahydrofuran (1 ml) was added to thesolution. The reaction mixture was stirred at 60° C. for 72 hours. Thereaction solution was diluted with water. The diluted solution wasextracted with a mixed solution of ethyl acetate and ether (1:1). Theextract was washed with water and then a saturated brine, dried overanhydrous magnesium sulfate and then evaporated. The residue waspurified by column chromatography on silica gel (n-hexane:ethylacetate=4:1) to give the title compound (220 mg) having the followingphysical data.

TLC (n-hexane:ethyl acetate=4:1): Rf 0.23; MS: m/e 487, 442, 426, 396,231.

REFERENCE EXAMPLE 20 4-(3-hydroxypropyl)phenyl2-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether ##STR50##

Sodium hydride (185 mg) was added to a solution of3-(4-hydroxyphenyl)propanol (560 mg) in tetrahydrofuran (6 ml). Themixture was stirred at room temperature under an atmosphere of argon.After the evolution of hydrogen finished, hexamethylphosphoramide (3 ml)was added to the solution. A solution of the tosyl compound (1.5 g),which was prepared with using the alcohol prepared in reference example7 by the same procedure as reference example 18, inhexamethylphosphoramide (6 ml) was added dropwise to this solution. Thesolution was stirred at 80° C. all night. The reaction solution waspermitted to stand for a moment. Water was added to the solution. Thesolution was slightly acidified with 2N hydrochloric acid and extractedwith ethyl acetate (150 ml). The organic layer was washed with, inorder, a saturated aqueous solution of sodium bicarbonate, an aqueoussolution of sodium thiosulfate, water and then saturated brine, driedover anhydrous sodium sulfate and then evaporated.

The residue was purified by column chromatography on silica gen(n-hexane:ethyl acetate=2:1) to give the title compound (1.22 g) havingthe following physical data.

NMR: δ 7.09 (2H, d), 6.80 (2H, d), 4.86 (2H, s), 4.17 (2H, m), 3.66 (2H,q), 3.62 (3H, s), 3.63 (4H, m), 2.20 (3H, s), 2.15 (3H, s), 2.10 (3H,s), 1.95-1.80 (4H, m), 1.35 (3H, s).

REFERENCE EXAMPLE 21 T-butyl2-(6-methoxymethoxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethoxyacetate##STR51##

The alcohol (200 mg) prepared in reference example 7 was dissolved inmethylene chloride (3 ml). A 20% aqueous solution of sodium hydroxide (3ml) was added to this solution. Tetrabutylammonium hydrogen sulfate (46mg) and tert-butyl α-bromoacetate (0.55 ml) were added to the solution.The mixture was stirred with violence at room temperature for 48 hours.The reaction mixture was extracted with chloroform. The extract waswashed with water and then saturated brine, dried over anhydrousmagnesium sulfate and then evaporated. The residue was purified bycolumn chromatography on silica gel (n-hexane:ethyl acetate=9:1) to givethe title compound (220 mg) having the following physical data.

TLC (n-hexane:ethyl acetate=4:1): Rf 0.54; MS: m/e 408, 363, 352, 335,307, 277, 231, 203.

REFERENCE EXAMPLE 222-(2-trifluoroacetoaminoethyl)-3,4-dihydro-2,5,7,8-tetramethyl-6-methoxymethoxybenzo[1,2-b]pyran##STR52##

2-(2-aminoethyl)-3,4-dihydro-2,5,7,8-tetramethyl-6-methoxymethoxybenzo[1,2-b]pyran (84.1 g), which was prepared with using the alcoholprepared in reference example 7 by the same procedure as in order,reference example 2→reference example 3, was dissolved in a mixedsolution of dimethylformamide (500 ml) and disopropylethylamine (60 ml).Ethyl trifluoroacetate (41.0 ml) was added dropwise to the solution at5° C. The mixture was stirred at room temperature all night. Thereaction mixture was evaporated. The residue was extracted with a mixedsolution of ethyl acetate and n-hexane (1:3). The extract was washedwith water and then brine, dried over anhydrous magnesium sulfate, andevaporated to give the title compound (109.9 g) having the followingphysical data.

TLC (n-hexane:ethyl acetate=5:1): Rf 0.28.

REFERENCE EXAMPLE 232-methylaminoethyl-2,5,7,8-tetramethyl-3,4-dihydro-6-methoxymethoxybenzo[1,2-b]pyran##STR53##

The benzopyran derivative (109.9 g) prepared in reference example 22 wasdissolved in dimethylformamide (500 ml). Sodium hydride (12.43 g) wasadded to the solution with cooling in an ice-bath. After the temperatureof the mixture was raised to room temperature, the mixture was stirredfor one hour. The mixture was cooled in an ice-bath and methyl iodidewas added thereto. The temperature of the mixture was rised to roomtemperature and the mixture stirred for one hour. A little water wasadded to the reaction solution. The solution was evaporated. A littlewater was added to the residue. The mixture was extracted with a mixedsolution of ethyl acetate and n-hexane (1:3). The extract was washedwith water and then brine, dried over anhydrous magnesium sulfate andthen evaporated. A 2N aqueous solution of sodium hydroxide (148.6 ml),methanol (300 ml) and tetrahydrofuran (30 ml) were added to the residue.The mixture was stirred at 5° C. for 38 hours. The reaction mixture wasevaporated. Water was added to the residue. The mixture was extractedwith ethyl acetate. The extract was evaporated. The residue was purifiedby column chromatography on silica gel(chloroform:methanol=10:1→3:1→5:2) to give the title compound (72.1 g)having the following phgysical data.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.31; MS: m/e 307, 262,219.

EXAMPLE 12-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl4-guanidinomethylbenzoate hydrochloride ##STR54##

4-guanidinomethylbenzoic acid hydrochloride (229 mg) was added to asolution of dicyclohexylcarbodiimide (206 mg) in dimethylformamide (2.5ml). After 10 minutes, a solution of the alcohol (prepared in referenceexample 1, 250 mg) in pyridine (2.5 ml) was added to the solution. Thesolution was stirred for 2 hours. The reaction solution was filtered.The filtrate was evaporated. The residue was purified by columnchromatography on silica gel (chloroform:methanol=6:1) to give the titlecompound (176 mg) having the following physical data.

TLC (chloroform:methanol=6:1): Rf 0.19; MS:m/e 425, 408, 383.

EXAMPLE 1(a)-1(m)

The compounds of the present invention shown in the following table 3were obtained with using the corresponding carboxylic acid and alcoholby the same procedure as example 1.

    TABLE 3      Example     No. Structure Name TLC MS m/e            1 (a)      ##STR55##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl4-guanidinobenzoatehydrochloride Rf 0.23(chloroform:methanol =3:1)     411, 394, 369, 248,232, 162, 120      1 (b)     ##STR56##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl4-guanidinomethylcyclohexane-carboxylate hydrochloride Rf 0.20(chloro     form:methanol = 4:1) 431, 414, 389, 302,288, 250, 164      1 (c)     ##STR57##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl5-guanidinopentanoatehydrochloride Rf 0.58(ethyl acetate:acetic      w     acid:ater =3:1:1) 391 (M.sup.+), 3.68,349, 250, 228, 164      1 (d)     ##STR58##      2-(2,5-dimethyl-6-hydroxy-7,8-dimethoxy-3,4-dihydro-2H-benzo[1,2-b]pyran     -2-yl)-ethyl 4-guanidinobenzoatehydrochloride Rf 0.55(ethyl acetate:aceti     c acid:water =4:1:1) 443, 426, 401, 282, 264, 196, 162, 120  1 (e)      ##STR59##      2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)ethyl     4-guanidinobenzoatehydrochloride Rf 0.60(ethyl acetate:acetic acid:water     =4:1:1) 433, 391, 272, 254,186, 120      1 (f)     ##STR60##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl(4-guanidinophenyl)acetatehydrochloride Rf 0.61(ethyl acetate:acetic     acid:water =3:1:1) 425 (M.sup.+), 383,262, 250, 232, 164,106  1 (g)      ##STR61##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl3-(4-guanidinophenyl)-propionate hydrochloride Rf 0.58(ethyl         a     acetate:cetic acid:water =3:1:1) 439 (M.sup.+), 397,276      1 (h)     ##STR62##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl4-guanidinocinnamatehydrochloride Rf 0.63(ethyl acetate:acetic     acid:water =3:1:1) 437 (M.sup.+), 395      1 (i)     ##STR63##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl3-guanidinobenzoatehydrochloride Rf 0.64(ethyl acetate:acetic     acid:water =3:1:1) 411 (M.sup.+), 394,369, 248      1 (j)     ##STR64##      2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)ethyl     4-guanidinomethylbenzoatehydrochloride Rf 0.46(ethyl acetate:acetic      w     acid:ater =4:1:1) 447, 405, 272, 254,187      1 (k)     ##STR65##      2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)ethyl     3-guanidinobenzoatehydrochloride Rf 0.45(ethyl acetate:acetic acid:water     =4:1:1) 433, 416, 391, 272,254, 186, 120      1 (l)     ##STR66##      2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)ethyl     4-guanidinocinnamatehydrochloride Rf 0.59(ethyl acetate:acetic acid:water      =4:1:1) 459, 417, 272, 186      1 (m)     ##STR67##      2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)e     thyl4-(1-methylguanidino)-benzoate hydrochloride Rf 0.47(ethyl acetate:ac     etic acid:water =4:1:1) 425,383, 262, 232,134

EXAMPLE 2N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-4-guanidinobenzamidehydrochloride ##STR68##

The amine (prepared in reference example 3, 1.0 g) and4-guanidinobenzoic acid hydrochloride (0.95 g) were dissolved in themixture of pyridine (5 ml) and dimethylformamide (5 ml).Dicyclohexylcarbodiimide (0.91 g) was added to the solution. The mixturewas stirred for 2.5 days. The reaction solution was fitered. Thefiltrate was evaporated. The residue was dissolved in methanol (10 ml),and 1N hydrochloric acid (6 ml) was added to the solution. The solutionwas evaporated. The residue was purified by column chromatography onsilica gel (methylene chloride:methanol=10:1) to give the title compound(275 mg) having the following physical data.

TLC (ethyl acetate:acetic acid:water=3:1:1): Rf 0.62; MS: m/e 410, 368,120.

EXAMPLE 2(a)-2(g)

The compounds of the present invention shown in the following table 4were obtained with using the corresponding carboxylic acid and amine bythe same procedure as example 2.

    TABLE 4      Example     No. Structure Name TLC MS m/e            2 (a)      ##STR69##      N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-y     l)-ethyl]-4-guanidinomethyl-cyclohexanecarboxamidehydrochloride Rf     0.53(ethyl acetate:acetic acid:water =3:1:1) 431      2 (b)     ##STR70##      N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-y     l)-ethyl]-4-guanidinomethyl-benzamide hydrochloride Rf 0.47(ethyl     acetate:acetic acid:water =3:1:1) 424, 407, 382      2 (c)     ##STR71##      N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-y     l)-ethyl]-5-guanidinopentan-amide hydrochloride Rf 0.50(ethyl acetate:ace     tic acid:water =3:1:1) 390, 373, 348      2 (d)     ##STR72##      N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-y     l)-ethyl]-3-guanidinobenzamidehydrochloride Rf 0.54(ethyl acetate:acetic     acid:water =4:1:1) 410, 368, 164, 120      2 (e)     ##STR73##      N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-y     l)-ethyl]-4-guanidinocinnam-amide hydrochloride Rf 0.48(ethyl acetate:ace     tic acid:water =4:1:1) 436, 394, 249, 146      2 (f)     ##STR74##      N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-naphtho[1,2-b]pyran-2     -yl)-ethyl]-3-guanidinobenzamidehydrochloride Rf 0.42(ethyl acetate:aceti     c acid:water =4:1:1) 432, 390, 271, 254      2 (g)     ##STR75##      N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-y     l)-ethyl]-4-guanidinophenoxy-acetamide hydrochloride Rf 0.32(ethyl     acetate:acetic acid:water =12:2:1) 440, 398, 277,233, 203, 165,122,     109

EXAMPLE 31-amino-3-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]guanidinehydroiodide ##STR76##

The thiourea (prepared in reference example 5, 17.4 g) was dissolved inethanol (170 ml). A solution of methyl iodide (24.0 g) in ethanol (10.5ml) was added dropwise to the solution over 2 hours at room temperature.After confirmation of conclusion of the reaction by TLC, the solutionwas evaporated. The residue (24.3 g) was dissolved in methanol (170 ml).A solution of hydrazine hydride (5.65 g) in methanol (80 ml) was addeddropwise to the solution at room temperature. The solution was stirredfor 2 days. The reaction solution was evaporated. The residue waspurified by column chromatography on silica gel(chloroform:methanol=95:5→90:10) to give the title compound (19.6 g)having the following physical data.

TLC (ethyl acetate:acetic acid:water=10:2:1): Rf 0.51; MS: m/e 306, 291,276.

EXAMPLE 3

The compound of the present invention shown in the following table 5 wasobtained with using the thiourea (prepared with using the correspondingmethyl ester as starting material by the same procedure as, in orderreference example 1→reference example 2→reference example 3→referenceexample 4→reference example 5) by the same procedure as example 3.

                                      TABLE 5                                     __________________________________________________________________________    Example                                                                       No.  Structure                  Name          TLC     MS                      __________________________________________________________________________                                                          m/e                     3 (a)                                                                               ##STR77##                 1-amino-3-[2-(2,5-dimethyl- 6-hydroxy-7,8-                                    dimethoxy- 3,4-dihydro-2H-benzo[1,2-b]-                                       pyran-2-yl)ethyl guanidine hydroiodide                                                      Rf 0.32 (ethyl acetate:                                                       acetic acid: water =                                                          10:2:1) 338 (M.sup.+), 323,                                                           08, 197,                __________________________________________________________________________                                                          142                 

EXAMPLE 4 4-(3-aminoguamidinomethyl)benzyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether hydroiodide ##STR78##

The title compound (324 mg) having the following physical data wasobtained with using the alcohol (prepared in reference example 6, 569mg) by the same procedure as reference example 2, 3, 4 and 5 and example3.

TLC (ethyl acetate:acetic acid:water=10:2:1): Rf 0.4; MS: m/e 427, 412,277, 250.

EXAMPLE 4

The compound of the present invention shown in the following table 6 wasobtained with using the corresponding alcohol by the same procedure asexample 4.

                                      TABLE 6                                     __________________________________________________________________________    Example No.                                                                            Structure                                                            __________________________________________________________________________    4 (a)                                                                                   ##STR79##                                                           __________________________________________________________________________    Example No.                                                                             Name             TLC          MS m/e                                __________________________________________________________________________    4 (a)     4-(3-aminoguanidino)benzyl                                                                     Rf 0.43 (ethyl acetate:                                                                    413, 382, 250,                                  2-(6-hydroxy-2,5,7,8-                                                                          acetic acid:water =4:1:1)                                                                  232, 220, 165                                   tetramethyl-3,4-dihydro-2H-                                                   benzo[1,2-b]pyran-2-yl)ethyl                                                  ether hydroiodide                                                   __________________________________________________________________________

EXAMPLE 5 4-guanidinophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether hydrochloride ##STR80##

A saturated solution of hydrochloric acid in ethanol (100 ml) was addedto a solution of the amine (61 g) prepared in reference example 10 inethanol (250 ml). The solution was evaporated. The residue obtained waswashed well with ether and then dried. A 50 wt % aqueous solution ofcyanamide (27.0 ml) was added to a suspension of the crystal (65.9 g)thus obtained in ethanol (250 ml). The mixture was stirred at 80° C.,for one day. The reaction mixture was evaporated. The obtained crystalwas washed well with ether and recrystallized from a mixed solution ofethanol and ether to give the title compound (58.6 g) having thefollowing physical data.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.47; MS: m/e 383, 366,341, 233, 220, 205, 165.

EXAMPLE 5-5

The compounds of the present invention shown in the following table 7were obtained with using the corresponding ether compounds, which wereprepared with using the alcohol prepared in reference example 7 by thesame procedure as, in order, reference example 8 (with the proviso thatthe corresponding nitro compounds were used instead of1-chloro-4-nitrobenzene)→reference example 9→reference example 10, bythe same procedure as example 5.

    TABLE 7      Example     No. Structure Name TLC MS m/e            5 (a)      ##STR81##      3-guanidinophenyl 2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[     1,2-b]-pyran-2-yl)ethyl etherhydrochloride Rf 0.44(ethyl acetate:acetic     acid:water =12:1:1) 383 (M.sup.+), 366,341, 220      5 (b)     ##STR82##      2-trifluoromethyl-4-guanidinophenyl 2-(6-hydroxy-2,5,7,8-tetramethyl-3,4     -dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl etherhydrochloride Rf 0.27 (ethy     l acetate:acetic acid:water =15:2:1) 451 (M.sup.+), 434,409, 288, 233,     219,165      5 (c)     ##STR83##      3-methyl-4-guanidinophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2     H-benzo[1,2-b]pyran-2-yl)ethylether hydrochloride Rf 0.29(ethyl acetate:a     cetic acid:water =15:2:1) 397 (M.sup.+), 234,205, 190, 165  5 (d)      ##STR84##      3-trifluoromethyl-4-guanidinophenyl 2-(6-hydroxy-2,5,7,8-tetramethyl-3,4     -dihydro-2H-benzo[1,2-b]-pyran-2-yl)ethyl etherhydrochloride  Rf     0.42(ethyl acetate:acetic acid:water =10:2:1) 452 (M.sup.+  + 1)  5 (e)      ##STR85##      4-guanidinophenyl 2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[     1,2-b]-pyran-2-yl)ethyl thioetherhydrochloride Rf 0.41(ethyl acetate:acet     ic acid:water =10:2:1) 400, 236, 165      5 (f)     ##STR86##      4-guanidinophenyl 2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b     ]-pyran-2-yl)ethyl etherhydrochloride Rf 0.38(ethyl acetate:acetic     acid:water =12:2:1) 406, 220, 187,164, 152      5 (g)     ##STR87##      4-guanidinophenyl 2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b     ]-pyran-2-yl)ethyl thioetherhydrochloride Rf 0.46(ethyl acetate:acetic     acid:water =12:2:1) 422, 236, 185

EXAMPLE 6 4-(3-aminoguanidino)phenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether hydroiodide ##STR88##

The title compound, of the present invention, having the followingphysical data was obtained with using the ether prepared in referenceexample 10 by the same procedure as, in order, reference example4→reference example 5→example 3. TLC (ethyl acetate:aceticacid:water=3:1:1): Rf 0.64; MS: m/e 398, 368, 341, 233, 205, 165.

EXAMPLE 6(a) AND 6(b)

The compounds, of the present invention, shown in the following table 8were obtained with using the corresponding ether compounds (which wasprepared with using the alcohol prepared in reference example 7 by thesame procedure as reference example 8 (with the proviso that thecorresponding nitro compound was used instead of1-chloro-4-nitrobenzene)→reference example 9 reference example 10 inorder) by the same procedure as example 6.

                                      TABLE 8                                     __________________________________________________________________________    Example No.                                                                            Structure                                                            __________________________________________________________________________    6 (a)                                                                                   ##STR89##                                                           6 (b)                                                                                   ##STR90##                                                           __________________________________________________________________________    Example No.                                                                          Name          TLC           MS m/e                                     __________________________________________________________________________    6 (a)  3-trifluoromethyl-4-(3-                                                                     Rf 0.18       466 (M.sup.+), 451, 436,                          aminoguanidino)phenyl 2-(6-                                                                 (methanol:chloroform = 1:4)                                                                 409, 303, 288,                                    hydroxy-2,5,7,8-tetramethyl-                                                                              165                                               3,4-dihydro-2H-benzo[1,2-b]-                                                  pyran-2-yl)ethyl ether                                                        hydroiodide                                                            __________________________________________________________________________    6 (b)  3-(3-aminoguanidino)phenyl                                                                  Rf 0.24       399 (M.sup.+  + 1)                                2-(6-hydroxy-2,5,7,8-                                                                       (methanol:chloroform = 1:9)                                     tetramethyl-3,4-dihydro-2H-                                                   benzo[1,2-b]pyran-2-yl)ethyl                                                  ether hydroiodide                                                      __________________________________________________________________________

EXAMPLE 7N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethoxy]phenyl]-4-guanidinobenzamidehydrochloride ##STR91##

The title compound, of the present invention, having the followingphysical data was obtained with using the ether prepared in referenceexample 10, by the same procedure as example 2. TLC (ethylacetate:acetic acid:water=4:1:1): Rf 0.50; MS: m/e 460, 165, 120.

EXAMPLE 7(a)-7(cc)

The compounds, of the present invention, shown in the following table 9were obtained the corresponding ether compound (which were prepared withusing the alcohol prepared in reference example 7 by the same procedureas reference example 8 (with the proviso that the correspondingnitrobenzene compounds were used instead of 1-chloro-4-nitrobenzene toprepared the compounds in example 7(c)-7(g))→reference example9→reference example 10 in order) and the corresponding appropriatecarboxylic acid by the same procedure as example 7.

    TABLE 9      Example     No. Structure Name TLC MS m/e            7 (a)      ##STR92##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]phenyl]-3-guanidino-benzamide hydrochloride Rf 0.45(ethyl     acetate:acetic acid:water =4:1:1) 460, 165, 120      7 (b)     ##STR93##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)ethoxy]phenyl]-4-guanidino-cinnamamide hydrochloride Rf 0.52(ethyl     acetate:acetic acid:water =4:1:1) 486, 368, 341, 165,146      7 (c)     ##STR94##      N-[3-trifluoromethyl-4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-b     enzo[1,2-b]pyran-2-yl)-ethoxy]phenyl]-4-guanidino-cinnamamide hydrochlori     de Rf 0.28(ethyl acetate:acetic acid:water =10:2:1) 689, 597 (M.sup.+  +     1)      7 (d)     ##STR95##      N-[3-acetoamido-4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo     [1,2-b]-pyran-2-yl)ethoxy]phenyl]-4-guanidinocinnamamidehydrochloride Rf     0.25(ethyl acetate:acetic acid:water =10:2:1) 586 (M.sup.+  + 1)  7 (e)      ##STR96##      N-[3-methoxy-4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,     2-b]pyran-2-yl)ethoxy]phenyl-4-guanidinocinnamamidehydrochloride Rf     0.38(methylenechloride:methanol:acetic acid =10:2:1) 652, 559  7 (f)      ##STR97##      N-[2-methyl-4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2     -b]pyran-2-yl)ethoxy]phenyl]-4-guanidinocinnamamidehydrochloride Rf     0.24(ethyl acetate:acetic acid:water =10:2:1) 695, 543 (M.sup.+  + 1)  7     (g)      ##STR98##      N-[3-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]phenyl]-4-guanidinocinnamamidehydrochloride Rf 0.62(ethyl     acetate:acetic acid:water =3:1:1) 486, 341, 146      7 (h)     ##STR99##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethylthio]phenyl]-4-guanidinobenzamidehydrochloride Rf 0.40(ethyl     acetate:acetic acid:water =12:2:1) 519, 355, 287,203, 185, 162  7 (i)      ##STR100##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H- benzo[1,2-b]pyran     -2-yl)-ethylthio]phenyl]-3-guanidinobenzamidehydrochloride Rf 0.46(ethyl     acetate:acetic acid:water =12:2:1) 519, 355, 313,287, 270, 162  7 (j)      ##STR101##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethylthio]phenyl]-4-guanidinocinnamamidehydrochloride Rf 0.37(ethyl      acetate:acetic acid:water =12:2:1) 545, 381, 205,188, 165, 146  7 (k)      ##STR102##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]-3-trifluoromethyl-phenyl]-4-guanidinobenzamidehydrochloride      Rf 0.31(ethyl acetate:acetic acid:water =10:2:1) 571, 407, 162,135, 120      7 (l)     ##STR103##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]phenyl]-4-guanidinophenoxyacetamidehydrochloride Rf     0.34(ethyl acetate:acetic acid:water =12:2:1) 533, 277, 185,165, 93, 75,     56      7 (m)     ##STR104##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]-3-trifluoromethyl-phenyl]-3-guanidinobenzamidehydrochloride      Rf 0.34(ethyl acetate:acetic acid:water =10:2:1) 571, 407, 205,165  7     (n)      ##STR105##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethoxy]phenyl]-4-guanidino-cinnamamide hydrochloride Rf 0.28(ethyl     acetate:acetic acid:water =12:2:1) 551, 365, 185      7 (o)     ##STR106##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethylthio]phenyl]-4-guanidino-benzamide hydrochloride Rf 0.25(ethyl     acetate:acetic acid:water =12:2:1) 541, 355, 162,120      7 (p)     ##STR107##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethylthio]phenyl]-3-guanidinobenzamidehydrochloride Rf 0.30 (ethyl     acetate:acetic acid:water =12:2:1) 541, 355, 162      7 (q)     ##STR108##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethylthio]phenyl]-4-guanidinocinnamamidehydrochloride Rf 0.24(ethyl     acetate:acetic acid:water =12:2:1) 567, 369, 277,185      7 (r)     ##STR109##       N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran     -2-yl)-ethoxy]phenyl]-4-guanidino-phenylthioacetamidehydrochloride Rf     0.28(ethyl acetate:acetic acid:water =15:2:1) 550, 385, 233,203, 165,     135      7 (s)     ##STR110##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethylthio]phenyl]-4-guanidinophenoxyacetamidehydrochloride Rf     0.20(ethyl acetate:acetic acid:water =15:2:1) 549, 385, 165  7 (t)      ##STR111##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethylthio]phenyl]-4-guanidinophenylthioacetamidehydrochloride Rf     0.28(ethyl acetate:acetic acid:water =15:2:1) 565, 399, 277,205, 185,     165,138, 93      7 (u)     ##STR112##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethylthio]phenyl]-3-guanidinophenoxyacetamidehydrochloride Rf     0.31(ethyl acetate:acetic acid:water =15:2:1) 549, 385, 165  7 (v)      ##STR113##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]phenyl]-3-guanidino-phenoxyacetamide hydrochloride Rf     0.23(ethyl acetate:acetic acid:water =15:2:1) 533, 369, 203,165  7 (w)      ##STR114##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethoxy]phenyl]-4-guanidino-benzamide hydrochloride Rf 0.26(ethyl     acetate:acetic acid:water =10:2:1) 525, 339, 187,162, 120  7 (x)      ##STR115##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethoxy]phenyl]-3-guanidino-benzamide hydrochloride Rf 0.29(ethyl     acetate:acetic acid:water =10:2:1) 525, 339, 225,187, 162, 135  7 (y)      ##STR116##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]phenyl]-4-guanidino-phenylacetamide hydrochloride Rf     0.25(ethyl acetate:acetic acid:water =12:2:1) 517, 353, 205,185, 165,     149,93      7 (z)     ##STR117##      N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-ethoxy]phenyl]-3-(4-guanidino-phenyl)propionamidehydrochloride Rf     0.27(ethyl acetate:acetic acid:water =12:2:1) 531, 367, 277,185, 165,     149,93      7 (aa)     ##STR118##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethylthio]phenyl]-4-guanidinophenoxyacetamidehydrochloride Rf 0.17(ethyl      acetate:acetic acid:water =15:2:1) 571, 385, 187,164, 152, 135   7 (bb)      ##STR119##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethoxy]phenyl]-3-guanidino-5-ethoxycarbonyl-benzamide hydrochloride Rf     0.31(ethyl acetate:acetic acid:water =15:2:1) 597, 411, 369,277, 185   7     (cc)      ##STR120##      N-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -ethoxy]phenyl]-4-guanidino-phenoxyacetamidehydrochloride Rf 0.14(ethyl     acetate:acetic acid:water =15:2:1) 555, 539, 405,369, 187, 164,152,     135

EXAMPLE 81-amino-3-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butyl]guanidinehydroiodide ##STR121##

The title compound, of the present invention, having the followingphysical data was obtained with using the methyl ester prepared inreference example 13 by the same procedure as reference example1→reference example 2→reference example 9→reference example 3→referenceexample 4→reference example 5→example 3 in order. TLC (ethylacetate:acetic acid:water=12:2:1): Rf 0.29; MS: m/e 335, 320, 304, 278.

EXAMPLE 9

N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butoxy]phenyl]-4-guanidinocinnamamidehydrochloride ##STR122##

The title compound, of the present invention, having the followingphysical data was obtained with using the methyl ester prepared inreference example 13 by the same procedure as reference example1→reference example 8→reference example 9→reference example 10→example 2(with the proviso that 4-guanidinocinnamic acid hydrochloride was usedinstead of 4-guanidinobenzoic acid hydrochloride) in order.

TLC (ethyl acetate:acetic acid:water=3:1:1): Rf 0.57; MS: m/e 514, 370,261, 205.

EXAMPLE 9-9

The compounds, of the present invention, shown in the following table 10were obtained with using the methyl ester prepared in reference example13 or the corresponding appropriate methyl ester by the same procedureas example 9 (with the proviso that the corresponding carboxylic acidhydrochloride was used instead of 4-guanidinocinnamic acid hydrochlorideand the corresponding appropriate nitro compounds were used instead of1-chloro-4-nitrobenzene to prepare the compounds in example 9(c)-9(h),9(j)-9(l), 9(n) and 9(q).

    TABLE 10      Example     No. Structure Name TLC MS m/e            9 (a)      ##STR123##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butoxy]phenyl]-4-guanidinobenzamidehydrochloride Rf 0.23(ethyl     acetate:acetic acid:water =12:2:1) 530, 488, 369, 165,120  9 (b)      ##STR124##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butoxy]phenyl]-3-guanidinobenzamidehydrochloride Rf 0.27(ethyl     acetate:acetic acid:water =12:2:1) 530, 489, 368, 324,228, 165, 120  9     (c)      ##STR125##      N-[3-trifluoromethyl-4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-b     enzo[1,2-b]pyran-2-yl)-butoxy]phenyl]-3-guanidinobenzamidehydrochloride     Rf 0.37(ethyl acetate:acetic acid:water =12:2:1) 598, 557, 436, 393,297,     203, 165, 120      9 (d)     ##STR126##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butylthio]phenyl]-4-guanidinocinnamamidehydrochloride Rf 0.37(ethyl      acetate:acetic acid:water =12:2:1) 573, 409, 203,188, 165, 93  9 (e)      ##STR127##      N-[3-acetoamido-4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo     [1,2-b]-pyran-2-yl)butoxy]phenyl]-4-guanidinocinnamamidehydrochloride Rf     0.42(ethyl acetate:acetic acid:water =4:1:1) 614, 553, 461,369, 277,     1     211,85, 165, 137,93, 75, 56      9 (f)     ##STR128##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butylthio]phenyl]-4-guanidinobenzamidehydrochloride Rf 0.32(ethyl     acetate:acetic acid:water =12:2:1) 547, 383, 185,162, 135, 120,93  9 (g)      ##STR129##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butylthio]phenyl]-3-guanidinobenzamide hydrochloride Rf 0.35(ethyl     acetate:acetic acid:water =12:2:1) 547, 383, 369,277, 185, 165,93  9 (h)      ##STR130##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butoxy]-3-methoxyphenyl]-4-guanidinocinnamamidehydrochloride Rf     0.52(ethyl acetate:acetic acid:water =4:1:1) 587, 277, 185,165, 149,     93,75, 56      9 (i)     ##STR131##      N-[4-[4-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -butoxy]phenyl]-4-guanidino-cinnamamide hydrochloride Rf 0.29(ethyl     acetate:acetic acid:water =12:2:1) 579, 393, 185      9 (j)     ##STR132##      N-[4-[4-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -butylthio]phenyl]-4-guanidinobenzamidehydrochloride Rf 0.28(ethyl     acetate:acetic acid:water =12:2:1) 526, 407, 368      9 (k)     ##STR133##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butoxy]-3-trifluoromethyl-phenyl]-4-guanidinobenzamidehydrochloride      Rf 0.32(ethyl acetate:acetic acid:water =10:2:1) 599, 435, 351,165,     162, 135,120      9 (l)     ##STR134##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butoxy]-3-trifluoromethyl-phenyl]-4-guanidinocinnamamidehydrochlori     de Rf 0.24(ethyl acetate:acetic acid:water =10:2:1) 625, 461, 203,188,     165, 146,135      9 (m)     ##STR135##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butoxy]phenyl]-3-guanidino-5-ethoxycarbonylbenzamidehydrochloride     Rf 0.26(ethyl acetate:acetic acid:water =30:4:1) 603, 461, 439,369, 277,     185      9 (n)     ##STR136##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butylthio] phenyl]-3-guanidino-5-ethoxycarbonyl-benzamide hydrochlo     ride Rf 0.32(ethyl acetate:acetic acid:water =30:4:1) 604, 461, 369,277,     207, 185      9 (o)     ##STR137##      N-[4-[4-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -butoxy]phenyl]-4-guanidino-benzamide hydrochloride Rf 0.31(ethyl     acetate:acetic acid:water =10:2:1) 553, 367, 162      9 (p)     ##STR138##      N-[4-[4-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b]pyran-2-yl)     -butoxy]phenyl]-3-guanidino-benzamide hydrochloride Rf 0.34(ethyl     acetate:acetic acid:water =10:2:1) 553, 367, 162      9 (q)     ##STR139##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butylthio]phenyl]-4-guanidinophenylacetamidehydrochloride Rf     0.34(ethyl acetate:acetic acid:water =12:2:1) 561, 397, 300,203, 165,     149,106      9 (r)     ##STR140##      N-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-     2-yl)-butoxy]phenyl]-4-guanidinophenylacetamidehydrochloride Rf 0.32(ethy     l acetate:acetic acid:water =12:2:1) 545, 381, 165,149, 106

EXAMPLE 10 4-guanidinophenyl4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylether hydrochloride ##STR141##

The title compound, of the present invention, having the followingphysical data was obtained with using the methyl ester prepared inreference example 13 by the same procedure as reference example1→reference example 8→reference example 9→reference example 10→example 5in order.

TLC (ethyl acetate:acetic acid:water=15:2:1): Rf 0.21; MS: m/e 411, 369,256, 248, 165.

EXAMPLE 10-10

The compounds, of the present invention, shown in the following table 11were obtained with using the methyl ester prepared in reference example13 by the same procedure as example 10 (with the proviso that thecorresponding appropriate nitrobenzene compounds were used instead of1-chloro-4-nitrobenzene).

    TABLE 11      Example     No. Structure Name TLC MS m/e            10 (a)      ##STR142##      2-trifluoromethyl-4-guanidinophenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,4     -dihydro-2H-benzo[1,2-b]-pyran-2-yl)butyl etherhydrochloride Rf 0.24(ethy     l acetate:acetic acid:water =15:2:1) 480 (M.sup.+  + 1)      10 (b)     ##STR143##      3-guanidinophenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[     1,2-b]-pyran-2-yl)butyl etherhydrochloride Rf 0.45(ethyl acetate:acetic     acid: water =12:2:1) 411, 394, 369,248, 165      10 (c)     ##STR144##      4-guanidino-2-methoxyphenyl4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-     2H-benzo[1,2-b]pyran-2-yl)butylether hydrochloride Rf 0.39(ethyl         a     acetate:cetic acid:water =12:2:1) 441, 424, 399,278, 261, 205  10 (d)      ##STR145##      2-acetoamido-4-guanidino-phenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dih     ydro-2H-benzo[1,2-b]pyran-2-yl)butylether hydrochloride Rf 0.29(ethyl     acetate:acetic acid:water =12:2:1) 469, 305, 165,93      10 (e)     ##STR146##      4-guanidinophenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[     1,2-b]-pyran-2-yl)butyl thioetherhydrochloride Rf 0.43(ethyl acetate:acet     ic acid:water =10:2:1) 427, 410, 385,368, 264, 165      10 (f)     ##STR147##      4-guanidino-3-trifluoromethyl-phenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,     4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylether hydrochloride Rf 0.32(ethy     l acetate:acetic acid:water =15:2:1) 479, 462, 437,368, 316, 219,165  10     (g)      ##STR148##      2-guanidino-4-trifluoromethyl-phenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,     4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylether hydrochloride Rf 0.57(ethy     l acetate:acetic acid:water =15:2:1) 479, 462, 437,316      10 (h)     ##STR149##      4-guanidinophenyl 4-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho[1,2-b     ]-pyran-2-yl)butyl etherhydrochloride Rf 0.38(ethyl acetate:acetic     acid:water =12:2:1) 434, 248, 185      10 (i)     ##STR150##      2-guanidinophenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[     1,2-b]-pyran-2-yl)butyl thioetherhydrochloride Rf 0.37(chloroform:methano     l:acetic acid =80:20:1) 428, 264, 185, 165, 93      10 (j)     ##STR151##      3-guanidinophenyl 4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[     1,2-b]-pyran-2-yl)butyl thioetherhydrochloride Rf 0.38(chloroform:methano     l:acetic acid =80:20:1) 428, 264, 165,135, 93

EXAMPLE 111-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-3-(3-guanidinophenyl)ureahydrochloride ##STR152##

The title compound, of the present invention, having the followingphysical data was obtained with using the urea derivative prepared inreference example 14 by the same procedure as reference example 10 andexample 5 in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.28; MS: m/e 426.

EXAMPLE 121-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butyl]-3-(3-guanidinophenyl)ureahydrochloride ##STR153##

The title compound, of the present invention, having the followingphysical data was obtained with using the methyl ester prepared inreference example 13 by the same procedure as reference example1→reference example 2→reference example 9→reference example 3→referenceexample 14→reference example 10→example 5 in order.

MS: m/e 454, 290, 203, 177, 165, 151, 134, 108, 93:

IR (cm⁻¹): ν 3700-2700, 3333, 2938, 2361, 1669, 1593, 1554, 1494, 1452,1379, 1246, 1168, 1086, 682.

EXAMPLE 13N-(3-guanidinophenyl)-4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butanamidehydrochloride ##STR154##

The title compound, of the present invention, having the followingphysical data was obtained with using the amide compound prepared inreference example 16 by the same procedure as reference example9→reference example 10→example 5 in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.24;

MS: m/e 424, 407, 382, 291, 274.

EXAMPLE 14N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-3-ethoxycarbonyl-5-guanidinobenzamidehydrochloride ##STR155##

The title compound, of the present invention, having the followingphysical data was obtained with using the amide compound prepared inreference example 17 by the same procedure as reference example 10 andexample 5 in order. TLC (ethyl acetate:acetic acid:water=15:2:1): Rf0.24; MS: m/e 482, 440, 232, 220, 192, 164.

EXAMPLE 15 2-ethoxycarbonyl-4-guanidinophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether hydrochloride ##STR156##

The title compound, of the present invention, having the followingphysical data was obtained with using the ether compound prepared inreference example 19 by the same procedure as reference example9→reference example 10→example 5 in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.38;

MS: m/e, 455, 438, 413, 368, 341, 392.

EXAMPLE 16N-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butyl]-3-ethoxycarbonyl-5-guanidinobenzamidehydrochloride ##STR157##

The title compound, of the present invention, having the followingphysical data was obtained with using the methyl ester prepared inreference example 13 by the same procedure as reference example1→reference example 2→reference example 3→reference example 17→referenceexample 9→reference example 10→example 5 in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.54;

MS: m/e 510, 493, 468, 368, 236, 192, 165.

EXAMPLE 17N-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethoxy]phenyl]-3-ethoxycarbonyl-5-guanidinobenzamidehydrochloride ##STR158##

The title compound, of the present invention, having the followingphysical data was obtained with using the ether compound prepared inreference example 8 by the same procedure as reference example10→reference example 17→reference example 9→reference example 10→example5 in order.

TLC (ethyl acetate:acetic acid:water=15:2:1): Rf 0.53;

MS: m/e 575, 461, 411, 369, 277, 185, 93, 75.

EXAMPLE 18 2-ethoxycarbonyl-4-guanidinophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylether hydrochloride ##STR159##

The title compound, of the present invention, having the followingphysical data was obtained with using the methyl ester prepared inreference example 13 by the same procedure as reference example1→reference example 18→reference example 19→reference example9→reference example 10→example 5 in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.33;

MS: m/e 483, 466, 441, 395, 377, 368, 320, 313, 260, 231, 203, 181, 165.

EXAMPLE 19 4-[3-(3-aminoguanidino)propyl]phenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether hydroiodide ##STR160##

The title compound, of the present invention, having the followingphysical data was obtained with using the alcohol prepared in referenceexample 20 by the same procedure as reference example 2→referenceexample 3→reference example 4→reference example 5→example 3 in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.41;

MS: m/e 441, 426, 277, 262, 185, 165, 93, 75.

EXAMPLE 20 4-(3-aminoguanidino)phenyl4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylether hydroiodide ##STR161##

The title compound, of the present invention, having the followingphysical data was obtained with using the methyl ester prepared inreference example 13 by the same procedure as reference example1→reference example 8→reference example 9→reference example 10→referenceexample 4→reference example 5→example 3 in order.

TLC (ethyl acetate:acetic acid:water=10:2:1): Rf 0.36;

MS: m/e 451, 436, 426, 369, 261, 165.

EXAMPLE 21N-[2-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethoxy]ethyl]-4-guanidinocinnamamidehydrochloride ##STR162##

The title compound, of the present invention, having the followingphysical data was obtained with using tert-butyl ester prepared inreference example 21 by the same procedure as reference example1→reference example 2→reference example 3→example 2 (with the provisothat 4-guanidinocinnamic acid hydrochloride was used instead of4-guanidinobenzoic acid hydrochloride) in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.30;

MS: m/e 481, 317, 249, 205, 188, 165.

EXAMPLE 22N-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butyl]-4-guanidinocinnamamidehydrochloride ##STR163##

The title compound, of the present invention, having the followingphysical data was obtained with using the ester prepared in referenceexample 13 by the same procedure as reference example 1→referenceexample 2→reference example 9→reference example 3→example 2 (with theproviso that the corresponding appropriate carboxylic acid hydrochloridewas used instead of 4-guanidinobenzoic acid hydrochloride) in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.27;

MS: m/e 464, 422, 165, 146.

EXAMPLE 22 (a)N-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2,-b]pyran-2-yl)butyl]-2-(4-guanidinophenoxy)acetamidehydrochloride ##STR164##

The title compound, of the present invention, having the followingphysical data was obtained by the same procedure as example 22.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.25;

MS: m/e 469, 305, 185, 165, 152, 93, 75.

EXAMPLE 232-[7-(3-aminoguanidino)hept-2-enyl]-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2,-b]pyranhydroiodide ##STR165##

The title compound, of the present invention, having the followingphysical data was obtained with using the alcohol prepared in referenceexample 7 by the same procedure as reference example 11→referenceexample 12 (with the proviso that the corresponding appropriate esterwas used instead of methyl(triphenylphosphoranylidene)acetate)→reference example 1→referenceexample 2→reference example 3→reference example 4→reference example5→example 3 in order.

TLC (ethyl acetate:acetic acid:water=10:2:1): Rf 0.44;

IR(cm⁻¹): ν 3411, 2931, 1657, 1419, 1376, 1343, 1260, 1220, 1162, 1088,476.

EXAMPLE 24N-methyl-N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-4-guanidinocinnamamidehydrochloride ##STR166##

The title compound, of the present invention, having the followingphysical data was obtained with using the benzopyran derivativesprepared in reference example 23 by the same procedure as referenceexample 9→example 2 (with the proviso that the corresponding appropriatecarboxylic acid hydrochloride was used instead of 4-guanidinobenzoicacid hydrochloride) in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.44;

MS: m/e 451, 287.

EXAMPLE 24 (a)N-benzyl-N-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethyl]-4-guanidinocinnamamidehydrochloride ##STR167##

The title compound, of the present invention, having the followingphysical data was obtained with using the compound, which was preparedwith using the benzopyran derivative prepared in reference example 22 bythe same procedure as reference example 23 (with the proviso that benzylbromide was used instead of methyl iodide), by the same procedure asexample 24.

TLC (ethyl acetate: acetic acid: water=12:2:1): Rf 0.38;

MS: m/e 527, 363, 188.

EXAMPLE 25N-methyl-N-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butyl]-4-guanidinocinnamamidehydrochloride ##STR168##

The title compound, of the present invention, having the followingphysical data was obtained with using2-(4-aminobutyl)2,5,7,8-tetramethyl-3,4-dihydro-6-methoxymethoxybenzo[1,2-b]pyran,which was prepared with using the ester prepared in reference example 13by the same procedure as reference example 1→reference example2→reference example 3 in order, by the same procedure as example 24.

TLC (ethyl acetate: acetic acid: water=12:2:1): Rf 0.38;

IR (cm⁻¹): ν 3333, 2939, 1677, 1646, 1598, 1515, 1456, 1255, 1168, 1088.

EXAMPLE 26 2-(3-aminoguanidino)ethyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether hydrochloride ##STR169##

The title compound, of the present invention, having the followingphysical data was obtained with using the benzopyran derivative preparedin reference example 18 by the same procedure as reference example 8(with the proviso that 2-nitroethanol was used instead ofp-chloronitrobenzene)→reference example 9→ reference example10→reference example 4→reference example 5→example 3 in order.

TLC (ethyl acetate:acetic acid:water=12:2:1): Rf 0.32;

IR (cm⁻¹): ν 3333, 2927, 1657, 1456, 1379, 1257, 1156, 1111, 1088;

MS: m/e 351, 336, 321, 165.

EXAMPLE 27 4-guanidinophenyl2-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethoxy]phenyl]ethylether hydrochloride ##STR170##

The title compound, of the present invention, having the followingphysical data was obtained with using the benzopyran derivative preparedin reference example 18 by the same procedure as reference example 8(with the proviso that p-(2-hydroxyethyl)phenol was used instead ofp-chloronitrobenzene)→reference example 18→reference example 8 (with theproviso that p-mercaptonitrophenol was used instead ofp-chloronitrobenzene)→reference example 9→reference example 10→example 5in order.

TLC (ethyl acetate:acetic acid:water=15:2:1): Rf 0.39;

IR(cm⁻¹): ν 3387, 2929, 1669, 1633, 1513, 1250, 1089, 1019, 817.

EXAMPLE 27(a)-27(k)

The compounds, of the present invention, shown in the following table 12were obtained with using the benzopyran derivative prepared in referenceexample 18 by the same procedure as example 27 (with the proviso thatthe corresponding appropriate compounds were used instead ofp-(2-hydroxyethyl)phenol and p-mercaptonitrophenol).

    TABLE 12      Example     No. Structure Name TLC MS m/e            27 (a)      ##STR171##      4-guanidinophenyl 2-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-ben     zo[1,2-b]-pyran-2-yl)ethoxy]ethyl etherhydrochloride Rf 0.29(ethyl     acetate:acetic acid:water =15:2:1) 427, 410, 385,264      27 (b)     ##STR172##      4-guanidinophenyl 2-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-ben     zo[1,2-b]-pyran-2-yl)ethylthio]ethylether hydrochloride Rf 0.40 (ethyl     acetate:acetic acid:water =15:2:1) 443, 369, 295,221      27 (c)     ##STR173##      4-guanidinophenyl 2-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-ben     zo[1,2-b]-pyran-2-yl)ethoxy]ethylthioether hydrochloride Rf 0.39(ethyl     acetate:acetic acid:water =15:2:1) 443, 426, 401,280      27 (d)     ##STR174##      3-guanidinophenyl 2-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b]-pyran-2-yl)ethoxy]phenyl]-ethyl thioether hydrochloride Rf     0.42(ethyl acetate:acetic acid: water =15:2:1) 519, 477, 352,232, 165     27 (e)      ##STR175##      4-guanidinophenyl 2-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b]-pyran-2-yl)ethoxy]phenyl]-ethyl ether hydrochloride Rf     0.35(ethyl acetate:acetic acid:water =15:2:1) 503, 461, 233,165  27 (f)      ##STR176##      4-guanidinophenyl 3-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b]-pyran-2-yl)ethoxy]phenyl]-propyl ether hydrochloride Rf     (     0.33ethyl acetate:acetic acid:water =15:2:1) 518, 384, 354,285, 205,     9     185,3      27 (g)     ##STR177##      3-guanidinophenyl 2-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b]pyran-2-yl)-ethoxy]phenyl]ethyl etherhydrochloride Rf     0.38(ethyl acetate:acetic acid:water =15:2:1) 503, 461, 352,340, 232,     205,165      27 (h)     ##STR178##      3-guanidinophenyl 3-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b] pyran-2-yl)-ethoxy]phenyl]propyl etherhydrochloride Rf     0.37(ethyl acetate:acetic acid:water =15:2:1) 517, 475, 165,164  27 (i)      ##STR179##      4-guanidinophenyl 3-[4-[2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b]pyran-2-yl)-ethoxy]phenyl]propylthioether hydrochloride Rf     0.37(ethyl acetate:acetic acid:water =15:2:1) 533, 491, 259,165, 125  27     (j)      ##STR180##       4-guanidinophenyl 2-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphth     o-[1,2-b]pyran-2-yl)ethoxy]-phenyl]ethyl etherhydrochloride Rf 0.5(ethyl     acetate:acetic acid:water =15:2:1) 526, 340, 187,151, 135, 121,93  27     (k)      ##STR181##      4-guanidinophenyl 2-[4-[2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-naphtho     -[1,2-b]pyran-2-yl)ethoxy]-phenyl]ethyl thioetherhydrochloride Rf     0.5(ethyl acetate:acetic acid:water =15:2:1) 542, 356, 187,167, 121

EXAMPLE 28 3-guanidinophenyl2-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butoxy]phenyl]ethylether hydrochloride ##STR182##

The title compound, of the present invention, having the followingphysical data was obtained with using the benzopyran derivative, whichwas prepared with using the ester prepared in reference example 13 bythe same procedures as reference example 1→reference example 18 inorder, by the same procedure as example 27 (with the proviso that3-nitrophenol was used instead of p-mercaptonitrophenol).

TLC (chloroform: methanol=4: 1): Rf 0.39;

IR(cm-1): ν 3377, 2932, 1741, 1678, 1585, 1512, 1494, 1459, 1343, 1246,1113, 1085.

EXAMPLE 28(a)-28(c)

The compounds, of the present invention, shown in the following table 13were obtained with using the benzopyran derivatives, which were preparedwith using the ester prepared in reference example 13 by the sameprocedure as reference example 1→reference example 18 in order, by thesame procedure as example 28 (with the proviso that the correspondingappropriate compounds were used instead of 3-nitrophenol).

    TABLE 13      Example     No. Structure Name TLC MS M/e            28 (a)      ##STR183##      4-guanidinophenyl 2-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b]-pyran-2-yl)butoxy]phenyl]-ethyl ether hydrochloride Rf     0.33(chloroform:methanol:acetic acid =80:20:1) 532, 368, 284,185, 165,     93      28 (b)     ##STR184##      3-guanidinophenyl 2-[4-[ 4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H     -benzo[1,2-b]-pyran-2-yl)butoxy]phenyl]-ethyl thioether hydrochloride Rf     0.4(chloroform:methanol:acetic acid =80:20:1) 548, 384, 300,203, 165  28     (c)      ##STR185##      4-guanidinophenyl 2-[4-[4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-     benzo[1,2-b]-pyran-2-yl)butoxy]phenyl]-ethyl thioether hydrochloride Rf     0.3(chloroform:methanol:acetic acid =80:20:1) 548, 384, 165

EXAMPLE 29 4-guanidinophenyl6-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)-n-hexylthioether hydrochloride ##STR186##

The title compund, of the present invention, having the followingphysical data was obtained with using the ester prepared in referenceexample 13 by the same procedure as reference example 1→referenceexample 11→reference example 12→reference example 13→reference example1→reference example→18→reference example 8 (with the proviso that4-mercaptonitrophenol was used instead ofp-chloronitrobenzene)→reference example 9→reference example 10→example 5in order.

TLC (ethyl acetate:acetic acid:water=10:2:1): Rf 0.39;

MS: m/e 455, 438, 413, 165.

EXAMPLE 29(a) 4-guanidinophenyl6-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)-n-hexylether hydrochloride ##STR187##

The title compound, of the present invention, having the followingphysical data was obtained with using the ester prepared in referenceexample 13 by the same procedure as example 29 (with the proviso thatp-chloronitrobenzene was used instead of 4-mercaptonitrophenol).

TLC (ethyl acetate:acetic acid:water=10:2:1): Rf 0.37;

MS: m/e 439, 422, 397, 276, 165, 109.

PREPARATIVE EXAMPLE

The following components were admixed in conventional method and punchedout to obtain 100 tablets each containing 50 mg of active ingredient.

    ______________________________________                                        2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-                                                           5     g                                          benzo[1,2-b]pyran-2-yl)ethyl 4-guanidinomethylbenzoate                        hydrochloride                                                                 Cellulose calcium glycolate  0.2   g                                          (distintegrating agent)                                                       Magnesium stearate           0.1   g                                          (lubricating agent)                                                           Microcrystaline cellulose    4.7   g                                          ______________________________________                                    

What is claimed is:
 1. A benzopyran derivative of the formula:##STR188## wherein R^(1a) is hydrogen, C1-4 alkyl or C1-4 alkoxy; or twoR^(1a) taken together with 7th- and 8th-carbon to which they areattached form C6 carbocyclic ring;R^(2a) is hydrogen or C1-4 alkyl;R^(3a) is hydrogen, C2-4 acyl or benzoyl; na is 1-3; Ya is C1-7alkylene, C2-7 alkenylene or C2-7 alkynylene; Ma isi) bond or ii) agroup of the formula: --Da--Ba; Da isi) --O-- or ii) --S--; Ba isi) C1-4alkylene; Za isi) bond or ii) --O--; Wa is a group of the formula:--W1a--Aa--W2a; Aa isi) a group of the formula: ##STR189## Ea is i)bond, ii) --O-- or iii) --S--; ○Ga is C4-10 carbocyclic or C4-10carbocyclic ring substituted by one to three C1-4 alkyl, C1-4 alkoxy,halogen, a group of the formula: --COOR^(7a), trihalomethyl oracetamido; W1a and W2a each, independently, isi) bond ii) C1-4 alkylene,iii) C2-4 alkenylene or iv) C2-4 alkynylene R^(4a) is hydrogen or C1-4alkyl; R^(5a) is hydrogen, C1-4 alkyl or amino R^(7a) is hydrogen orC1-4 alkyl; with the proviso that:i) Da is bonded to Ya and Ba is bondedto Za; ii) Ea is bonded to W1a and ○Ga is bonded to W2a; iii) a doubleor triple bond in alkenylene or alkynylene is not directly bonded tooxygen; and iv) when Aa represents ##STR190## W1a does not represent abond; or pharmaceutically acceptable acid addition salt thereof.
 2. Acompound according to claim 1, wherein ○ is benzene or naphthalene ring,or benzene or naphthalene ring substituted by one to three C1-4 alkyl,C1-4 alkoxy, halogen, a group of the formula: --COOR^(7a) trihalomethylor acetamido.
 3. A compound according to claim 1, wherein Za is bond. 4.A compound according to claim 2, wherein Za is --O--.
 5. A compoundaccording to claim 1, wherein Ga is C4-7 cycloalkane or C4-7 cycloalkanesubstituted by one to three C1-4 alkyl, C1-4 alkoxy, halogen, a group ofthe formula: --COOR^(7a), trihalomethyl or acetamido.
 6. A compoundaccording to claim 1, wherein Za is --O--.
 7. A compound according toclaim 1, which is: 4-guanidinophenyl4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylthioether; 4-guanidinophenyl6-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)n-hexylthioether; 2-ethoxycarbonyl-4-guanidinophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether; 4-guanidinophenyl2-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)ethylether; 4-guanidinophenyl4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylether; 2-trifluoromethyl-4-guanidinophenyl4-(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-benzo[1,2-b]pyran-2-yl)butylether; or 4-guanidinophenyl2-(2,5-dimethyl-6-hydroxy-3,4-dihydro-2H-napththo[1,2-b]pyran-2-yl)ethylether.